{"content":"<li class=\"n-box-item date-title\" data-end=\"1519707599\" data-start=\"1519621200\" data-txt=\"Monday, December 23, 2019\">Monday, February 26, 2018</li><li class=\"n-box-item sa-box-item\" data-id=\"3334396\" data-ts=\"1519695132\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SN\" target=\"_blank\">SN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3334396-sanchez-energy-to-pay-dividends-on-convertible-preferred-stock-in-cash\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sanchez Energy to pay dividends on convertible preferred stock in cash</a></h4><ul>     <li>Sanchez Energy (NYSE:<a href='https://seekingalpha.com/symbol/SN' title='Sanchez Energy Corporation'>SN</a>)&nbsp;<font color='green'>+3.4%</font> after-hours after announcing it will <a href=\"https://seekingalpha.com/pr/17084989-sanchez-energy-pay-dividends-series-series-b-convertible-perpetual-preferred-stock-cash\" target=\"_blank\">pay dividends</a> on series A and B convertible perpetual preferred shares in cash rather than in common stock.</li>     <li>SN will pay a quarterly dividend of nearly $0.61/share on the 4.875% series A convertible shares and more than $0.81/share on the 6.5% series B shares.</li><li>SN finished +4% in today's trade following its <a href=\"https://seekingalpha.com/news/3334027-sanchez-energy-eps-1_01\" target=\"_blank\">Q4 earnings</a> report.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3334396\" data-linked=\"Sanchez Energy to pay dividends on convertible preferred stock in cash\" data-tweet=\"$SN $SNEC - Sanchez Energy to pay dividends on convertible preferred stock in cash https://seekingalpha.com/news/3334396-sanchez-energy-to-pay-dividends-on-convertible-preferred-stock-in-cash?source=tweet\" data-url=\"https://seekingalpha.com/news/3334396-sanchez-energy-to-pay-dividends-on-convertible-preferred-stock-in-cash\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:32 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>17&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3334393\" data-ts=\"1519691819\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DISCA\" target=\"_blank\">DISCA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3334393-discovery-sells-majority-of-education-unit-to-private-equity-firm-for-120m\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Discovery sells majority of education unit to private-equity firm for $120M</a></h4><ul>   <li>Discovery Communications (NASDAQ:<a href='https://seekingalpha.com/symbol/DISCA' title='Discovery Inc A'>DISCA</a>) is selling majority ownership of Discovery Education to private-equity firm Francisco Partners.</li>    <li>The all-cash deal comes at $120M. Discovery will retain a minority stake and license the Discovery Education brand to the business.</li>    <li>After the closing, expected in the first half of the year, Discovery Education CEO Bill Goodwyn and his team will operate the unit as a stand-alone business.</li>    <li>Discovery shares were a top gainer among big media stocks today, with <a href='https://seekingalpha.com/symbol/DISCA' title='Discovery Inc A'>DISCA</a> rising to close <font color='green'>up 4.8%</font>; shares are still on the move after hours, <font color='green'>up 2.4%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3334393\" data-linked=\"Discovery sells majority of education unit to private-equity firm for $120M\" data-tweet=\"$DISCA $DISCB $DISCK - Discovery sells majority of education unit to private-equity firm for $120M https://seekingalpha.com/news/3334393-discovery-sells-majority-of-education-unit-to-private-equity-firm-for-120m?source=tweet\" data-url=\"https://seekingalpha.com/news/3334393-discovery-sells-majority-of-education-unit-to-private-equity-firm-for-120m\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:36 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3334375\" data-ts=\"1519684971\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CRC\" target=\"_blank\">CRC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3334375-california-resourcesminus-3-production-costs-disappoint\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">California Resources -3% as production, costs disappoint</a></h4><ul>     <li>California Resources (NYSEMKT:<a href='https://seekingalpha.com/symbol/CRC' title='California Resources Corporation'>CRC</a>) <font color='red'>-3%</font> after-hours despite posting a much smaller than expected <a href=\"https://seekingalpha.com/news/3334322-california-resources-beats-0_24-misses-revenue\" target=\"_blank\">Q4 loss</a>, as revenues come in flat Y/Y at $455M, coming in well short of expectations.</li>     <li>CRC says production fell 6.6% Y/Y to 126K boe/day for Q4, and slid 7.8% Y/Y to 140K boe/day for FY 2017, mostly because of reduced volumes of natural gas from the San Joaquin Basin; the company forecasts Q1 production of 120K-125K boe/day at production costs of $19.25-$20.75/boe.</li>     <li>Q4 production costs were $19.64/boe, compared to $17.50/boe in the prior-year quarter, driven by an increase in energy costs; for FY 2017, production costs were $18.64/boe vs. $15.61/ble in 2016.</li><li>CRC expects FY&nbsp;2018 capex of $425M-$450M vs. $371M in 2017.</li>     <li>Year-end proved reserves of 618M boe, up from 568M boe at year-end 2016, organically replacing 119% of reserves from the capital program, excluding price revisions.</li></ul><div class=\"tiny-share-widget\" data-id=\"3334375\" data-linked=\"California Resources -3% as production, costs disappoint\" data-tweet=\"$CRC - California Resources -3% as production, costs disappoint https://seekingalpha.com/news/3334375-california-resourcesminus-3-production-costs-disappoint?source=tweet\" data-url=\"https://seekingalpha.com/news/3334375-california-resourcesminus-3-production-costs-disappoint\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:42 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3334371\" data-ts=\"1519684609\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/THC\" target=\"_blank\">THC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3334371-after-hours-gainers-losers-2-26-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">After Hours Gainers / Losers (2/26/2018)</a></h4><ul>     <li><b>Top gainers:</b> <a href='https://seekingalpha.com/symbol/THC' title='Tenet Healthcare Corporation'>THC</a> <font color='green'>+6.6%</font>. <a href='https://seekingalpha.com/symbol/PANW' title='Palo Alto Networks'>PANW</a> <font color='green'>+5.3%</font>. <a href='https://seekingalpha.com/symbol/INSG' title='Inseego Corp.'>INSG</a> <font color='green'>+3.6%</font>. <a href='https://seekingalpha.com/symbol/TTS' title='Tile Shop Holdings, Inc.'>TTS</a> <font color='green'>+2.9%</font>. <a href='https://seekingalpha.com/symbol/ZN' title='Zion Oil & Gas Inc'>ZN</a> <font color='green'>+2.1%</font>.</li><li><b>Top losers:</b> <a href='https://seekingalpha.com/symbol/AKRX' title='Akorn, Inc.'>AKRX</a> <font color='red'>-39.9%</font>. <a href='https://seekingalpha.com/symbol/NTRI' title='Nutrisystem Inc'>NTRI</a> <font color='red'>-27.1%</font>. <a href='https://seekingalpha.com/symbol/VERI' title='Veritone'>VERI</a> <font color='red'>-14.9%</font>. <a href='https://seekingalpha.com/symbol/FIT' title='Fitbit, Inc.'>FIT</a> <font color='red'>-10.8%</font>. <a href='https://seekingalpha.com/symbol/CRZO' title='Carrizo Oil & Gas, Inc.'>CRZO</a> <font color='red'>-6.5%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3334371\" data-linked=\"After Hours Gainers / Losers (2/26/2018)\" data-tweet=\"$THC $THC $PANW - After Hours Gainers / Losers (2/26/2018) https://seekingalpha.com/news/3334371-after-hours-gainers-losers-2-26-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3334371-after-hours-gainers-losers-2-26-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:36 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3334367\" data-ts=\"1519683907\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WDR\" target=\"_blank\">WDR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3334367-waddell-reed-cut-to-junk-moody-s-bloomberg\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Waddell &amp; Reed cut to junk by Moody\u2019s - Bloomberg</a></h4><ul>     <li>Moody's cut the asset manager's outlook from stable to negative.</li>     <li>The rating agency says \"that sustained net outflows and inconsistent investment performance have materially weakened Waddell &amp; Reed&rsquo;s (NYSE:<a href='https://seekingalpha.com/symbol/WDR' title='Waddell & Reed Financial Inc'>WDR</a>) competitive position within the industry.\"</li>     <li>Previously: <a href=\"https://seekingalpha.com/news/3330401-waddell-and-reed-financial-reports-4-percent-m-m-higher-aum-months-steady-aum\" target=\"_blank\">Waddell &amp; Reed Financial reports 4% M/M higher AUM after months of steady AUM</a> (Feb. 13)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3334367\" data-linked=\"Waddell &amp; Reed cut to junk by Moody\u2019s - Bloomberg\" data-tweet=\"$WDR - Waddell &amp; Reed cut to junk by Moody\u2019s - Bloomberg https://seekingalpha.com/news/3334367-waddell-reed-cut-to-junk-moody-s-bloomberg?source=tweet\" data-url=\"https://seekingalpha.com/news/3334367-waddell-reed-cut-to-junk-moody-s-bloomberg\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:25 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3334357\" data-ts=\"1519682461\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IDTI\" target=\"_blank\">IDTI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3334357-piper-jaffray-initiates-integrated-device-macom-and-qorvo\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Piper Jaffray initiates Integrated Device, MACOM, and Qorvo</a></h4><ul><li>        Piper Jaffray <a href=\"https://www.streetinsider.com/New+Coverage/Piper+Jaffray+Starts+Integrated+Device+Technology+%28IDTI%29+at+Overweight/13864891.html\" target=\"_blank\">initiates</a> Integrated Device Technology (NASDAQ:<a href='https://seekingalpha.com/symbol/IDTI' title='Integrated Device Technology, Inc.'>IDTI</a>) coverage with an Overweight rating and a $33 price target, a nearly 8% upside to today&rsquo;s close.&nbsp;</li><li>               The firm initiates MACOM (NASDAQ:<a href='https://seekingalpha.com/symbol/MTSI' title='MACOM Technology Solutions Holdings, Inc.'>MTSI</a>) with a Neutral rating and a $22 price target, which is 14 cents below today&rsquo;s close.&nbsp;</li><li>               Qorvo (NASDAQ:<a href='https://seekingalpha.com/symbol/QRVO' title='Qorvo, Inc'>QRVO</a>) was initiated with an Overweight rating.</li><li>               Source: Briefing.com.&nbsp;</li><li>               Qorvo shares are&nbsp;<font color='green'>up 0.1%</font>&nbsp;aftermarket. &nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3334357\" data-linked=\"Piper Jaffray initiates Integrated Device, MACOM, and Qorvo\" data-tweet=\"$IDTI $IDTI $MTSI - Piper Jaffray initiates Integrated Device, MACOM, and Qorvo https://seekingalpha.com/news/3334357-piper-jaffray-initiates-integrated-device-macom-and-qorvo?source=tweet\" data-url=\"https://seekingalpha.com/news/3334357-piper-jaffray-initiates-integrated-device-macom-and-qorvo\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:01 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3334355\" data-ts=\"1519682346\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AKRX\" target=\"_blank\">AKRX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3334355-akron-down-34-after-hours-on-fresenius-inquiry-data-integrity\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Akron down 34% after hours on Fresenius inquiry into data integrity</a></h4><ul><li>Akorn (NASDAQ:<a href='https://seekingalpha.com/symbol/AKRX' title='Akorn, Inc.'>AKRX</a>) slumps&nbsp;<font color='red'>34%</font>&nbsp;after hours on a <a href=\"https://twitter.com/zbiotech/status/968239234011357186\" target=\"_blank\">disclosure</a> by acquirer Fresenius Kabi that it is investigating alleged breaches of FDA data integrity by Akorn related to product development. It adds that the outcome of the inquiry may have an effect on the merger.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3259326-analysts-say-akron-fresenius-deal-fairly-priced\" target=\"_blank\">Analysts say Akron/Fresenius deal fairly priced</a> (April 25, 2017)</li></ul><div class=\"tiny-share-widget\" data-id=\"3334355\" data-linked=\"Akron down 34% after hours on Fresenius inquiry into data integrity\" data-tweet=\"$AKRX - Akron down 34% after hours on Fresenius inquiry into data integrity https://seekingalpha.com/news/3334355-akron-down-34-after-hours-on-fresenius-inquiry-data-integrity?source=tweet\" data-url=\"https://seekingalpha.com/news/3334355-akron-down-34-after-hours-on-fresenius-inquiry-data-integrity\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:59 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>15&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3334345\" data-ts=\"1519681364\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CRZO\" target=\"_blank\">CRZO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3334345-carrizo-oilminus-6-ahead-of-double-digit-increase-in-2018-oilfield-service-costs\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Carrizo Oil -6% ahead of &#39;double-digit increase&#39; in 2018 oilfield service costs</a></h4><ul>     <li>Carrizo Oil &amp;&nbsp;Gas (NASDAQ:<a href='https://seekingalpha.com/symbol/CRZO' title='Carrizo Oil & Gas, Inc.'>CRZO</a>) <font color='red'>-6%</font> after-hours despite posting modestly better than expected <a href=\"https://seekingalpha.com/news/3334300-carrizo-oil-and-gas-beats-0_01-beats-revenue\" target=\"_blank\">Q4 earnings</a> and revenues.</li>     <li>CRZO says Q4 production of 62,417 boe/day rose 39% Y/Y and ended above the high-end of its guidance range, with crude oil production of 40.2K bbl/day coming in 40% above the year-ago quarter.</li>     <li>CRZO forecasts FY 2018 production of 58.5K-60.1K boe/day, or ~10% annual growth at the midpoint of the range, while expecting capital spending of $750M-$800M, assuming a \"double-digit increase\" in oilfield service costs.</li>     <li>Year-end 2017 proved reserves were 261.7M boe, up 31% Y/Y; crude oil reserve rose 30% Y/Y to 167.4M barrels, the company's highest-ever level of crude oil reserves.</li></ul><div class=\"tiny-share-widget\" data-id=\"3334345\" data-linked=\"Carrizo Oil -6% ahead of &#39;double-digit increase&#39; in 2018 oilfield service costs\" data-tweet=\"$CRZO - Carrizo Oil -6% ahead of &#39;double-digit increase&#39; in 2018 oilfield service costs https://seekingalpha.com/news/3334345-carrizo-oilminus-6-ahead-of-double-digit-increase-in-2018-oilfield-service-costs?source=tweet\" data-url=\"https://seekingalpha.com/news/3334345-carrizo-oilminus-6-ahead-of-double-digit-increase-in-2018-oilfield-service-costs\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:42 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>62&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3334342\" data-ts=\"1519681205\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VLRX\" target=\"_blank\">VLRX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3334342-valeritas-eps-of-3_10\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Valeritas EPS of -$3.10</a></h4><ul><li>Valeritas (NASDAQ:<a href='https://seekingalpha.com/symbol/VLRX' title='Valeritas Holdings, Inc.'>VLRX</a>): Q4 EPS of -$3.10 may not be comparable to consensus of -$1.59.</li><li>Revenue of $5.8M (+20.8% Y/Y) <font color='green'>beats by $0.2M</font>.</li><li>Shares <font color='green'>+4.45%</font>.</li><li><a href='https://seekingalpha.com/pr/17084792-valeritas-reports-fourth-quarter-full-year-2017-financial-results'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3334342\" data-linked=\"Valeritas EPS of -$3.10\" data-tweet=\"$VLRX - Valeritas EPS of -$3.10 https://seekingalpha.com/news/3334342-valeritas-eps-of-3_10?source=tweet\" data-url=\"https://seekingalpha.com/news/3334342-valeritas-eps-of-3_10\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:40 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3334341\" data-ts=\"1519681136\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/THC\" target=\"_blank\">THC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3334341-tenet-q4-top-line-up-2-non-gaap-earnings-up-509-cash-flow-up-268-shares-up-4-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Tenet Q4 top line up 2%; non-GAAP earnings up 509%; cash flow up 268%; shares up 4% after hours</a></h4><ul><li>Tenet Healthcare (NYSE:<a href='https://seekingalpha.com/symbol/THC' title='Tenet Healthcare Corporation'>THC</a>): <a href=\"https://seekingalpha.com/pr/17084873-tenet-reports-results-fourth-quarter-ended-december-31-2017\" target=\"_blank\">Q4 results</a> ($M): Revenues: 5,303 (+1.7%).</li><li>Net loss: (229) (-189.9%); loss/share: (2.27) (-187.3%); non-GAAP EPS: 1.40 (+508.7%); non-GAAP EBITDA: 840 (+29.2%); cash flow ops:&nbsp; 491 (+267.6%).</li><li><strong>2018 guidance</strong>: Revenues: $17.9B - 18.3B; non-GAAP EBITDA; $2.5B - 2.6B; operating income: $95M - 105M; EPS: $0.92 - 1.02; non-GAAP EPS: $0.73 - 1.07.</li><li>Shares are up&nbsp;<font color='green'>4%</font>&nbsp;after hours on light volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3334341\" data-linked=\"Tenet Q4 top line up 2%; non-GAAP earnings up 509%; cash flow up 268%; shares up 4% after hours\" data-tweet=\"$THC - Tenet Q4 top line up 2%; non-GAAP earnings up 509%; cash flow up 268%; shares up 4% after hours https://seekingalpha.com/news/3334341-tenet-q4-top-line-up-2-non-gaap-earnings-up-509-cash-flow-up-268-shares-up-4-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3334341-tenet-q4-top-line-up-2-non-gaap-earnings-up-509-cash-flow-up-268-shares-up-4-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:38 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3334339\" data-ts=\"1519680897\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PANW\" target=\"_blank\">PANW</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3334339-palo-alto-networksplus-5_7-on-q2-beats-upside-guidance-billingsplus-20\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Palo Alto Networks +5.7% on Q2 beats, upside guidance; billings +20%</a></h4><ul><li>        Palo Alto Networks (NYSE:<a href='https://seekingalpha.com/symbol/PANW' title='Palo Alto Networks'>PANW</a>)&nbsp;<font color='green'>pushes up 5.7%&nbsp;</font>aftermarket following Q2 results that beat EPS and revenue estimates with a 28.3% Y/Y revenue growth.</li><li>               Upside Q3 guidance: Revenue, $538 to $548M (consensus: $533.12M); Product revenue, $193M to $196M (+18% to 19% Y/Y); billings, $665M to $680M (+22% to 25%); EPS, $0.94 to $0.96 (consensus: $0.81).</li><li>               Upside FY18 guidance: Revenue, $2.19B to $2.22B (consensus: $2.17B); Product revenue, $810M to $820M (+14% to 16%); billings, $2.715 to $2.77B (+18% to 21%); EPS, $3.84 to $3.91 (consensus: $3.40).&nbsp;</li><li>               Billings and revenue breakdown: Billings totaled $674.6M, up 20% on the year. Deferred revenue grew 33% to $2B.&nbsp;</li><li>               Key metrics: Cash flow form operations, $243.7M; FCF, $218.1M; total operating expenses, $414.9M; cash and equivalents, $2.4B.&nbsp;</li><li>                  Tax reform impact: Company changed non-GAAP effective tax rate rom 31% to 22%, which resulted in a Q2 EPS benefit of $0.11. &nbsp;   </li><li>               Earnings call is scheduled for 4:30 PM Eastern Time with a webcast available <a href=\"http://investors.paloaltonetworks.com/\" target=\"_blank\">here</a>.&nbsp;</li><li>               <a href=\"https://seekingalpha.com/pr/17084855-palo-alto-networks-reports-fiscal-second-quarter-2018-financial-results\" target=\"_blank\">Press release</a>&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3334312-palo-alto-networks-beats-0_07-beats-revenue\" target=\"_blank\">Palo Alto Networks beats by $0.07, beats on revenue</a> (Feb. 26)</li></ul><div class=\"tiny-share-widget\" data-id=\"3334339\" data-linked=\"Palo Alto Networks +5.7% on Q2 beats, upside guidance; billings +20%\" data-tweet=\"$PANW - Palo Alto Networks +5.7% on Q2 beats, upside guidance; billings +20% https://seekingalpha.com/news/3334339-palo-alto-networksplus-5_7-on-q2-beats-upside-guidance-billingsplus-20?source=tweet\" data-url=\"https://seekingalpha.com/news/3334339-palo-alto-networksplus-5_7-on-q2-beats-upside-guidance-billingsplus-20\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:34 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3334333\" data-ts=\"1519680621\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VERI\" target=\"_blank\">VERI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3334333-veritone-drops-after-deeper-loss-expected\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Veritone drops after deeper loss than expected</a></h4><ul>   <li>Veritone (NASDAQ:<a href='https://seekingalpha.com/symbol/VERI' title='Veritone'>VERI</a>) has <font color='red'>slipped 11.6%</font> after hours following <a href=\"https://seekingalpha.com/news/3334298-veritone-misses-0_18-misses-revenue\" target=\"_blank\">Q4 earnings</a> after posting a deeper loss than expected and missing on revenues despite heavy Y/Y gains.</li>    <li>Net loss widened to $12.8M from $9.9M; EBITDA was -$10.2M vs. a prior-year -$7.2M (and missing an expected -$7.8M).</li>    <li>Revenue breakout: Media agency revenues, $3.02M (up 36.9%); AI platform revenues, $477,000 (up 61.1%).</li>    <li>For Q1 on its aiWARE platform, it expects to add eight customers, 110 accounts, and 20 third-party cognitive engines (and one cognitive category), and is guiding to processing 1.9M total hours of video/audio content.</li>    <li><a href=\"http://investors.veritone.com\" target=\"_blank\">Conference call</a> to come at 4:30 p.m. ET.</li>    <li><a href=\"https://seekingalpha.com/pr/17084806-veritone-reports-financial-results-fourth-quarter-full-year-2017\" target=\"_blank\">Press release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3334333\" data-linked=\"Veritone drops after deeper loss than expected\" data-tweet=\"$VERI - Veritone drops after deeper loss than expected https://seekingalpha.com/news/3334333-veritone-drops-after-deeper-loss-expected?source=tweet\" data-url=\"https://seekingalpha.com/news/3334333-veritone-drops-after-deeper-loss-expected\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:30 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3334331\" data-ts=\"1519680514\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NTRI\" target=\"_blank\">NTRI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3334331-nutrisystem-craters-after-weak-revenue-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Nutrisystem craters after weak revenue guidance</a></h4><ul>     <li>The wheels have fallen off Nutrisystem (NASDAQ:<a href='https://seekingalpha.com/symbol/NTRI' title='Nutrisystem Inc'>NTRI</a>) after the company's guidance for&nbsp; fell short of expectations for the critical Q1 period and the full year.</li>     <li>The company sees revenue of $204-209M&nbsp;for Q1 vs. $241M consensus estimate .For the full year, Nutrisyustem anticipates revenue of $685-705M vs. $790M consensus.</li>     <li>Shares of Nutrisystem are&nbsp;<font color='red'>down 21%</font>&nbsp;in AH trading after shedding about 4% during the regular session before the earnings report hit.</li>     <li>Previously: <a href=\"https://seekingalpha.com/news/3334279-nutrisystem-beats-0_02-beats-revenue\" target=\"_blank\">Nutrisystem beats by $0.02, beats on revenue</a> (Feb. 26)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3334331\" data-linked=\"Nutrisystem craters after weak revenue guidance\" data-tweet=\"$NTRI - Nutrisystem craters after weak revenue guidance https://seekingalpha.com/news/3334331-nutrisystem-craters-after-weak-revenue-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3334331-nutrisystem-craters-after-weak-revenue-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:28 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>13&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3334323\" data-ts=\"1519680201\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FIT\" target=\"_blank\">FIT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3334323-fitbitminus-11-after-q4-miss-downbeat-revenue-and-profit-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Fitbit -11% after Q4 miss, downbeat revenue and profit guidance</a></h4><ul>   <li>Fitbit (NYSE:<a href='https://seekingalpha.com/symbol/FIT' title='Fitbit, Inc.'>FIT</a>) has slid in after-hours trade, <font color='red'>down 11%</font>, after <a href=\"https://seekingalpha.com/news/3334284-fitbit-misses-0_02-misses-revenue\" target=\"_blank\">Q4 earnings</a> missed on top and bottom lines and the company issued dim guidance for the current quarter and year head.</li>    <li>Double-digit revenue declines in the U.S. swamped solid gains in the rest of the world and triggered a miss of Street expectations.</li>    <li>Meanwhile, net losses narrowed heavily but the company missed analyst expectations for a break-even quarter, losing $45.5M.</li>    <li>Fitbit sold 5.4M wearables in the quarter; average selling price rose 20%, to $102/device thanks to adding in smartwatch Fitbit Ionic.</li>    <li>New devices (Fitbit Ionic, Alta HR, Fitbit Aria 2 and Fitbit Flyer) made up 36% of revenue.</li>    <li>Revenue by geography: U.S., $330.2M (down 13.4%); Americas ex-U.S., $46.7M (up 39.7%); EMEA, $155.1M (up 15.7%); APAC, $38.8M (up 55.9%).</li>    <li>For Q1, the company sees \"limited revenue from new product introduction,\" and guides to revenue of $240M-$255M -- a 15-20% drop, and well below consensus for $340.3M. It also sees EPS of -$0.21 to -$0.18, below expected -$0.09. Free cash flow should decline less than revenues and end up about -$25M.</li>    <li>For the full year, it's forecasting revenue of $1.5B (below consensus for $1.73B) and a negative impact on gross margins from device mix shift and fixed cost deleveraging.</li>    <li><a href=\"http://investor.fitbit.com\" target=\"_blank\">Conference call</a> to come at 5 p.m. ET.</li>    <li><a href=\"https://seekingalpha.com/pr/17084815-fitbit-reports-571m-q4-17-1_616b-fy-17-revenue\" target=\"_blank\">Press release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3334323\" data-linked=\"Fitbit -11% after Q4 miss, downbeat revenue and profit guidance\" data-tweet=\"$FIT - Fitbit -11% after Q4 miss, downbeat revenue and profit guidance https://seekingalpha.com/news/3334323-fitbitminus-11-after-q4-miss-downbeat-revenue-and-profit-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3334323-fitbitminus-11-after-q4-miss-downbeat-revenue-and-profit-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:23 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>27&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3334321\" data-ts=\"1519680123\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/THC\" target=\"_blank\">THC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3334321-tenet-healthcare-beats-0_15-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Tenet Healthcare beats by $0.15, beats on revenue</a></h4><ul><li>Tenet Healthcare (NYSE:<a href='https://seekingalpha.com/symbol/THC' title='Tenet Healthcare Corporation'>THC</a>): Q4 EPS of $1.40 <font color='green'>beats by $0.15</font>.</li><li>Revenue of $4.98B (+2.5% Y/Y) <font color='green'>beats by $110M</font>.</li><li>Shares <font color='green'>+3.3%</font>.</li><li><a href='https://seekingalpha.com/pr/17084873-tenet-reports-results-fourth-quarter-ended-december-31-2017'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3334321\" data-linked=\"Tenet Healthcare beats by $0.15, beats on revenue\" data-tweet=\"$THC - Tenet Healthcare beats by $0.15, beats on revenue https://seekingalpha.com/news/3334321-tenet-healthcare-beats-0_15-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3334321-tenet-healthcare-beats-0_15-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:22 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3334319\" data-ts=\"1519680066\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CLVS\" target=\"_blank\">CLVS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3334319-clovis-oncology-q4-rubraca-sales-17m-shares-down-1-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Clovis Oncology Q4 Rubraca sales: $17M; shares down 1% after hours</a></h4><ul><li>Clovis Oncology (NASDAQ:<a href='https://seekingalpha.com/symbol/CLVS' title='Clovis Oncology'>CLVS</a>) <a href=\"https://seekingalpha.com/pr/17084811-clovis-oncology-announces-2017-operating-results\" target=\"_blank\">Q4 results</a> ($M): Product sales: 17.0 (+999%) (Rubraca).</li><li>Net loss: (51.9) (+26.6%);non-GAAP net loss: (63.4) (+10.3%); loss/share: (1.04) (+43.2%); non-GAAP loss/share: (1.27) (+30.6%); cash flow ops (65.6) (-19.9%).</li><li>Amount of free Rubraca available under patient assistance program remained at 20% of overall supply. Range should remain relatively unchanged for the foreseeable future.</li><li>Shares are down&nbsp;<font color='red'>1%</font>&nbsp;after hours on light volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3334319\" data-linked=\"Clovis Oncology Q4 Rubraca sales: $17M; shares down 1% after hours\" data-tweet=\"$CLVS - Clovis Oncology Q4 Rubraca sales: $17M; shares down 1% after hours https://seekingalpha.com/news/3334319-clovis-oncology-q4-rubraca-sales-17m-shares-down-1-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3334319-clovis-oncology-q4-rubraca-sales-17m-shares-down-1-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:21 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3334316\" data-ts=\"1519680016\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SNHY\" target=\"_blank\">SNHY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3334316-sun-hydraulics-eps-in-line-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sun Hydraulics EPS in-line, beats on revenue</a></h4><ul><li>Sun Hydraulics (NASDAQ:<a href='https://seekingalpha.com/symbol/SNHY' title='Sun Hydraulics Corporation'>SNHY</a>): Q4 EPS of $0.27 in-line.</li><li>Revenue of $84.2M (+68.8% Y/Y) <font color='green'>beats by $1.68M</font>.</li><li>Shares <font color='green'>+2.4%</font>.</li><li><a href='https://seekingalpha.com/pr/17084865-sun-hydraulics-reports-fourth-quarter-full-year-2017-results'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3334316\" data-linked=\"Sun Hydraulics EPS in-line, beats on revenue\" data-tweet=\"$SNHY $HLIO - Sun Hydraulics EPS in-line, beats on revenue https://seekingalpha.com/news/3334316-sun-hydraulics-eps-in-line-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3334316-sun-hydraulics-eps-in-line-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:20 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3334312\" data-ts=\"1519679902\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PANW\" target=\"_blank\">PANW</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3334312-palo-alto-networks-beats-0_07-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Palo Alto Networks beats by $0.07, beats on revenue</a></h4><ul><li>Palo Alto Networks (NYSE:<a href='https://seekingalpha.com/symbol/PANW' title='Palo Alto Networks'>PANW</a>): Q2 EPS of $0.86 <font color='green'>beats by $0.07</font>.</li><li>Revenue of $542.4M (+28.3% Y/Y) <font color='green'>beats by $17.42M</font>.</li><li>Shares <font color='green'>+4%</font>.</li><li><a href='https://seekingalpha.com/pr/17084855-palo-alto-networks-reports-fiscal-second-quarter-2018-financial-results'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3334312\" data-linked=\"Palo Alto Networks beats by $0.07, beats on revenue\" data-tweet=\"$PANW - Palo Alto Networks beats by $0.07, beats on revenue https://seekingalpha.com/news/3334312-palo-alto-networks-beats-0_07-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3334312-palo-alto-networks-beats-0_07-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:18 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3334303\" data-ts=\"1519679708\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CDEV\" target=\"_blank\">CDEV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3334303-centennial-resource-beats-0_02-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Centennial Resource beats by $0.02, beats on revenue</a></h4><ul><li>Centennial Resource (NASDAQ:<a href='https://seekingalpha.com/symbol/CDEV' title='Centennial Resource Development'>CDEV</a>): Q4 EPS of $0.12 <font color='green'>beats by $0.02</font>.</li><li>Revenue of $166.1M (+402.7% Y/Y) <font color='green'>beats by $14.82M</font>.</li><li>Shares <font color='green'>+1.5%</font>.</li><li><a href='https://seekingalpha.com/pr/17084836-centennial-resource-development-announces-full-year-2017-results-2017-year-end-reserves-2018'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3334303\" data-linked=\"Centennial Resource beats by $0.02, beats on revenue\" data-tweet=\"$CDEV - Centennial Resource beats by $0.02, beats on revenue https://seekingalpha.com/news/3334303-centennial-resource-beats-0_02-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3334303-centennial-resource-beats-0_02-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:15 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3334276\" data-ts=\"1519677539\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WPG\" target=\"_blank\">WPG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3334276-bounce-underway-for-mall-names\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Bounce underway for mall names</a></h4><ul><li>Looking anywhere for some value in a pricey market, investors have taken an interest in the highly-roughed-up shopping center names.</li><li>Over the past three sessions, Washington Prime (NYSE:<a href='https://seekingalpha.com/symbol/WPG' title='Washington Prime Group, Inc.'>WPG</a>) is&nbsp;<font color='green'>up 14.7%</font>, CBL &amp; Associates (NYSE:<a href='https://seekingalpha.com/symbol/CBL' title='CBL & Associates Properties, Inc.'>CBL</a>)&nbsp;<font color='green'>7.3%</font>, DDR (DDR)&nbsp;<font color='green'>8.5%</font>, PREIT (NYSE:<a href='https://seekingalpha.com/symbol/PEI' title='Pennsylvania Real Estate Investment Trust'>PEI</a>)&nbsp;<font color='green'>8%</font>, and Kite Realty (NYSE:<a href='https://seekingalpha.com/symbol/KRG' title='Kite Realty Group Trust'>KRG</a>)&nbsp;<font color='green'>4.2%</font>, to name five.</li><li>The advance comes alongside an easing in interest pressure, with the 10-year Treasury yield at 2.86% this afternoon, after challenging 3% last week.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3334262-averages-add-another-1-percent\" target=\"_blank\">Averages add another 1%</a> (Feb. 26)</li></ul><div class=\"tiny-share-widget\" data-id=\"3334276\" data-linked=\"Bounce underway for mall names\" data-tweet=\"$WPG $WPG $CBL - Bounce underway for mall names https://seekingalpha.com/news/3334276-bounce-underway-for-mall-names?source=tweet\" data-url=\"https://seekingalpha.com/news/3334276-bounce-underway-for-mall-names\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:38 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3334274\" data-ts=\"1519677375\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WGO\" target=\"_blank\">WGO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3334274-rv-names-move-off-airstream-news\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">RV names move off Airstream news</a></h4><ul>     <li>Winnebago (NYSE:<a href='https://seekingalpha.com/symbol/WGO' title='Winnebago Industries, Inc.'>WGO</a>)&nbsp;<font color='green'>is up 5.0%</font>&nbsp;and LCI Industries (NYSE:<a href='https://seekingalpha.com/symbol/LCII' title='LCI Industries'>LCII</a>) is&nbsp;<font color='green'>2.7% higher</font>&nbsp;after a hefty investment from rival Thor Industries in its Airstream business lifts sentiment across the RV sector.</li><li>The Airstream news also has Camping World (<a href='https://seekingalpha.com/symbol/CWH' title='Camping World Holdings'>CWH</a> <font color='green'>+1.4%</font>) heading for the hills.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3334232-thor-industries-rallies-tipping-airstream-expansion\" target=\"_blank\">Thor Industries rallies after tipping Airstream expansion</a> (Feb. 26)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3334274\" data-linked=\"RV names move off Airstream news\" data-tweet=\"$WGO $WGO $LCII - RV names move off Airstream news https://seekingalpha.com/news/3334274-rv-names-move-off-airstream-news?source=tweet\" data-url=\"https://seekingalpha.com/news/3334274-rv-names-move-off-airstream-news\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:36 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3334270\" data-ts=\"1519676496\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SMMT\" target=\"_blank\">SMMT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3334270-summits-ezutromid-reduced-muscle-inflammation-in-mid-stage-dmd-study-shares-ahead-2\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Summit&#39;s ezutromid reduced muscle inflammation in mid-stage DMD study; shares ahead 2%</a></h4><ul><li>Summit Therapeutics (<a href='https://seekingalpha.com/symbol/SMMT' title='Summit Therapeutics'>SMMT</a> <font color='green'>+1.8%</font>) <a href=\"https://seekingalpha.com/pr/17083881-summit-announces-new-analysis-showing-ezutromid-significantly-reduced-muscle-inflammation\" target=\"_blank\">announces </a>that a further analysis of the results from a Phase 2 clinical trial, <a href=\"https://clinicaltrials.gov/ct2/show/NCT02858362?term=phaseout&amp;rank=1\" target=\"_blank\">PhaseOutDMD</a>, assessing DMD candidate ezutromid showed a statistically significant decrease in muscle inflammation from baseline at week 24 in tissue samples.</li><li>The company says the decrease, measured by magnetic resonance spectroscopy transverse relaxation time T2 (MRS-T2), underlines ezutromid's activity to stabilize muscle fiber membranes which reduces muscle fiber damage and inflammation.</li><li>Also observed was a statistically significant decrease from baseline in T2 relaxation time in the calf muscle, a key muscle used to monitor DMD progression. Increases in T2 relaxation time correlate with the advancement of disease and loss of functional ability.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3325201-summit-therapeutics-ezutromid-shows-positive-effect-mid-stage-dmd-study-shares-5-percent\" target=\"_blank\">Summit Therapeutics' ezutromid shows positive effect in mid-stage DMD study; shares up 5% premarket</a> (Jan. 25)</li></ul><div class=\"tiny-share-widget\" data-id=\"3334270\" data-linked=\"Summit&#39;s ezutromid reduced muscle inflammation in mid-stage DMD study; shares ahead 2%\" data-tweet=\"$SMMT - Summit&#39;s ezutromid reduced muscle inflammation in mid-stage DMD study; shares ahead 2% https://seekingalpha.com/news/3334270-summits-ezutromid-reduced-muscle-inflammation-in-mid-stage-dmd-study-shares-ahead-2?source=tweet\" data-url=\"https://seekingalpha.com/news/3334270-summits-ezutromid-reduced-muscle-inflammation-in-mid-stage-dmd-study-shares-ahead-2\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:21 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3334269\" data-ts=\"1519676220\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FSLR\" target=\"_blank\">FSLR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3334269-first-solarplus-5-deutsche-bank-defends-shares-following-fridays-loss\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">First Solar +5% as Deutsche Bank defends shares following Friday&#39;s loss</a></h4><ul>     <li>First Solar (<a href='https://seekingalpha.com/symbol/FSLR' title='First Solar, Inc.'>FSLR</a> <font color='green'>+4.9%</font>) recoups much of its post-earnings loss that occurred despite a smaller than expected <a href=\"https://seekingalpha.com/news/3333496-first-solar-beats-0_06-misses-revenue\" target=\"_blank\">Q4 loss</a> and <a href=\"https://seekingalpha.com/news/3333587-first-solar-minus-2-percent-q4-revenue-tumbles-two-thirds-vs-q3\" target=\"_blank\">upside FY 2018 guidance</a>.</li>     <li>Deutsche Bank analysts <a href=\"https://www.benzinga.com/analyst-ratings/analyst-color/18/02/11258842/deutsche-bank-3-reasons-to-remain-bullish-on-first-sola\" target=\"_blank\">maintain a Buy rating</a> with a $75 price target after Friday's nearly 7% shellacking, as they expect capacity expansion in the U.S. considering FSLR's 9 GW backlog and near-term potential to sell out through 2020.</li>     <li>The firm notes FSLR expects its S6 modules to offset S4 module discounts and generate a premium to c-Si panels, which it says could drive 2019 average selling prices above 2018 levels.</li>     <li>Deutsche Bank also says FSLR has the biggest backlog in U.S. business, which generates higher price points and better margins than international bookings.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3334269\" data-linked=\"First Solar +5% as Deutsche Bank defends shares following Friday&#39;s loss\" data-tweet=\"$FSLR - First Solar +5% as Deutsche Bank defends shares following Friday&#39;s loss https://seekingalpha.com/news/3334269-first-solarplus-5-deutsche-bank-defends-shares-following-fridays-loss?source=tweet\" data-url=\"https://seekingalpha.com/news/3334269-first-solarplus-5-deutsche-bank-defends-shares-following-fridays-loss\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:17 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3334264\" data-ts=\"1519674940\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RCM\" target=\"_blank\">RCM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3334264-technology-top-gainers-losers-of-2_55-pm-2-26-18\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Technology - Top Gainers / Losers as of 2.55 pm (2/26/18)</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/RCM' title='R1 RCM Inc.'>RCM</a> <font color='green'>+19%</font>. <a href='https://seekingalpha.com/symbol/NIHD' title='NII Holdings, Inc.'>NIHD</a> <font color='green'>+13%</font>. <a href='https://seekingalpha.com/symbol/VERI' title='Veritone'>VERI</a> <font color='green'>+13%</font>. <a href='https://seekingalpha.com/symbol/DTRM' title='Determine, Inc.'>OTC:DTRM</a> <font color='green'>+11%</font>. <a href='https://seekingalpha.com/symbol/GTT' title='GTT Communications, Inc.'>GTT</a> <font color='green'>+10%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/I' title='Intelsat SA'>I</a> <font color='red'>-15%</font>. <a href='https://seekingalpha.com/symbol/MYSZ' title='MySize Inc.'>MYSZ</a> <font color='red'>-15%</font>. <a href='https://seekingalpha.com/symbol/QBAK' title='Qualstar Corporation'>QBAK</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/MAXR' title='Maxar Technologies Inc'>MAXR</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/TST' title='TheStreet, Inc.'>TST</a> <font color='red'>-7%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3334264\" data-linked=\"Technology - Top Gainers / Losers as of 2.55 pm (2/26/18)\" data-tweet=\"$RCM $RCM $NIHD - Technology - Top Gainers / Losers as of 2.55 pm (2/26/18) https://seekingalpha.com/news/3334264-technology-top-gainers-losers-of-2_55-pm-2-26-18?source=tweet\" data-url=\"https://seekingalpha.com/news/3334264-technology-top-gainers-losers-of-2_55-pm-2-26-18\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:55 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3334220\" data-ts=\"1519674792\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TLRA\" target=\"_blank\">TLRA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3334220-telaria-down-22-on-q4-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Telaria down 22% on Q4 results</a></h4><ul><li>Telaria (<a href='https://seekingalpha.com/symbol/TLRA' title='Telaria, Inc.'>TLRA</a> <font color='red'>-22.5%</font>) reported Q4 revenue increase of 45% Y/Y to $15M, almost meeting consensus.</li><li>Operating loss margin <font color='green'>recovered </font>to -7.41%.</li><li>Reported adjusted EBITDA of $3M and adjusted EBITDA margin of 20%.</li><li>Guidance: 1Q18 Revenue of&nbsp; $8.5-10M and adjusted EBITDA -$4.5 to -3.5M. FY18 Revenue $58-62M and adjusted EBITDA of $5-8M.</li><li>Telaria appointed Rick Song as Chief Revenue Office. His previous stint included building successful sales teams at Microsoft, iHeart and Zefr.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3334044-telaria-misses-0_03-misses-revenue\" target=\"_blank\">Telaria misses by $0.03, misses on revenue</a> (Feb. 26 2018)</li></ul><div class=\"tiny-share-widget\" data-id=\"3334220\" data-linked=\"Telaria down 22% on Q4 results\" data-tweet=\"$TLRA - Telaria down 22% on Q4 results https://seekingalpha.com/news/3334220-telaria-down-22-on-q4-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3334220-telaria-down-22-on-q4-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:53 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3334263\" data-ts=\"1519674441\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EXK\" target=\"_blank\">EXK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3334263-endeavour-silver-misses-0_01-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Endeavour Silver misses by $0.01, beats on revenue</a></h4><ul><li>Endeavour Silver (NYSE:<a href='https://seekingalpha.com/symbol/EXK' title='Endeavour Silver Corp.'>EXK</a>): Q4 EPS of $0.02 <font color='red'>misses by $0.01</font>.</li><li>Revenue of $41.6M (+45.2% Y/Y) <font color='green'>beats by $1.57M</font>.</li><li>Shares <font color='green'>+1.9%</font>.</li><li><a href='https://seekingalpha.com/pr/17083823-endeavour-silver-reports-2017-financial-results-conference-call-10am-pst-1pm-est-today'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3334263\" data-linked=\"Endeavour Silver misses by $0.01, beats on revenue\" data-tweet=\"$EXK - Endeavour Silver misses by $0.01, beats on revenue https://seekingalpha.com/news/3334263-endeavour-silver-misses-0_01-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3334263-endeavour-silver-misses-0_01-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:47 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3334262\" data-ts=\"1519674362\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3334262-averages-add-another-1\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Averages add another 1%</a></h4><ul><li>A bit more than an hour before the bell, the S&amp;P 500 and Nasdaq are&nbsp;<font color='green'>higher by 1%</font>&nbsp;and the Dow by&nbsp;<font color='green'>1.4%</font>.</li><li>Among the largest S&amp;P advancers is none other than Berkshire Hathaway,&nbsp;<font color='green'>up 3.7%</font>&nbsp;following Q4 results, the release of the annual letter, and The Oracle's <a href=\"https://seekingalpha.com/news/3334056-buffett-talks-shop-annual-letter\" target=\"_blank\">appearance on CNBC</a> this morning. Investors hoping for Buffett to reverse his longstanding distaste of paying a dividend were disappointed, but he did seem open to returning capital via buybacks should no tasty big acquisition opportunities arise.</li><li>The 10-year Treasury yield is flat at 2.86%.</li></ul><div class=\"tiny-share-widget\" data-id=\"3334262\" data-linked=\"Averages add another 1%\" data-tweet=\"Averages add another 1% https://seekingalpha.com/news/3334262-averages-add-another-1?source=tweet\" data-url=\"https://seekingalpha.com/news/3334262-averages-add-another-1\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:46 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3334261\" data-ts=\"1519674202\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LUCRF\" target=\"_blank\">LUCRF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3334261-lucara-diamondplus-18-on-blockchain-deal-names-thomas-new-ceo\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Lucara Diamond +18% on blockchain deal; names Thomas as new CEO</a></h4><ul>     <li>Lucara Diamond (<a href='https://seekingalpha.com/symbol/LUCRF' title='Lucara Diamond Corp.'>OTCPK:LUCRF</a> <font color='green'>+18.2%</font>) surges after <a href=\"https://seekingalpha.com/pr/17083564-lucara-diamond-announces-acquistion-clara-diamond-solutions-corporation\" target=\"_blank\">agreeing to acquire</a> blockchain company Clara Diamond Solutions for $29M, joining larger rival DeBeers in exploring blockchain technology.</li>     <li>Clara is operator of a digital platform selling rough diamonds as well as blockchain technology that seeks to track gems through the industry supply chain.</li><li>Separately, Lucara appoints co-founder and director Eira Thomas as its <a href=\"https://seekingalpha.com/pr/17083565-lucara-announces-board-management-changes\" target=\"_blank\">new CEO</a>, replacing the retiring William Lamb.</li>     <li>Lucara currently operates a mine in Botswana famous for its big stones, including a 1,109-carat diamond in 2016.</li></ul><div class=\"tiny-share-widget\" data-id=\"3334261\" data-linked=\"Lucara Diamond +18% on blockchain deal; names Thomas as new CEO\" data-tweet=\"$LUCRF - Lucara Diamond +18% on blockchain deal; names Thomas as new CEO https://seekingalpha.com/news/3334261-lucara-diamondplus-18-on-blockchain-deal-names-thomas-new-ceo?source=tweet\" data-url=\"https://seekingalpha.com/news/3334261-lucara-diamondplus-18-on-blockchain-deal-names-thomas-new-ceo\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:43 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3334188\" data-ts=\"1519673835\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AWI\" target=\"_blank\">AWI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3334188-on-armstrong-worlds-q4-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">More on Armstrong World&#39;s Q4 results</a></h4><ul><li>Armstrong World (<a href='https://seekingalpha.com/symbol/AWI' title='Armstrong World Industries, Inc.'>AWI</a> <font color='red'>-4%</font>) reported 9.1% Y/Y revenue growth to $214.3M meeting analyst estimates; Segment revenue: Architectural Specialties +49% Y/Y to $36.8M which was driven by higher volume, led by the Tectum acquisition and increased new construction activity, Mineral Fiber +3.4% Y/Y to $177.6M.</li><li>Q4 operating margin <font color='green'>improved 361 bps</font>&nbsp;to 24.13%. Mineral fiber segment&rsquo;s operating margin&nbsp;<font color='red'>declined 154 bps</font>&nbsp;to 22.57% and architectural specialties&nbsp;<font color='green'>improved 310 bps</font>&nbsp;to 19.3%.</li><li>2018 guidance: Net Sales +5-7% Y/Y and adjusted Free Cash Flow +20-30%.</li><li>&ldquo;Our guidance for 2018 anticipates a slightly more favorable macro-economic climate, but is largely driven by factors within our control. We expect to deliver improved Average Unit Value in our sales, drive productivity savings greater than inflation, and drive cost savings from our restructuring actions in St. Helens and our corporate back office, especially in the second half of the year,&rdquo; said CFO Brian MacNeal.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3334048-armstrong-world-misses-0_17-misses-revenue\" target=\"_blank\">Armstrong World misses by $0.17, misses on revenue</a> (Feb. 26)</li></ul><div class=\"tiny-share-widget\" data-id=\"3334188\" data-linked=\"More on Armstrong World&#39;s Q4 results\" data-tweet=\"$AWI - More on Armstrong World&#39;s Q4 results https://seekingalpha.com/news/3334188-on-armstrong-worlds-q4-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3334188-on-armstrong-worlds-q4-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:37 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3334258\" data-ts=\"1519673190\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CVRR\" target=\"_blank\">CVRR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3334258-cvr-refining-eyes-49m-saving-on-biofuels-trump-weighs-policy-change\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CVR Refining eyes $49M saving on biofuels as Trump weighs policy change</a></h4><ul>     <li>CVR Energy (<a href='https://seekingalpha.com/symbol/CVRR' title='CVR Refining, LP'>CVRR</a> <font color='red'>-2.5%</font>) estimates spending $200M this year, <a href=\"https://www.bloomberg.com/news/articles/2018-02-26/icahn-may-save-49-million-as-trump-weighs-biofuel-policy-change\" target=\"_blank\">nearly $50M less than in 2017</a>, to comply with the U.S. biofuel mandate, according to a <a href=\"https://www.sec.gov/Archives/edgar/data/1558785/000155878518000019/cvrr2017form10-kx12312017.htm\" target=\"_blank\">new 10-K filing</a>.</li>     <li>While CVR has not provided a direct reason for the savings, CEO David Lamp expressed optimism during <a href=\"https://seekingalpha.com/article/4149697-cvr-refinings-cvrr-ceo-dave-lamp-q4-2017-results-earnings-call-transcript\" target=\"_blank\">last Thursday's earnings conference call</a> that the Trump administration eventually would change the mandate.</li>     <li>Trump reportedly is discussing potential policy changes today with EPA chief Pruitt, Agriculture Secretary Perdue and Vice Pres. Mike Pence and tomorrow will present options to four key U.S. senators involved in the issue.</li>     <li>CVR&rsquo;s filing also reiterates that the U.S. Attorney&rsquo;s Office for the Southern District of New York contacted the company last September to ask for information related to director Carl Icahn&rsquo;s activities in his role as advisor to Trump.</li></ul><div class=\"tiny-share-widget\" data-id=\"3334258\" data-linked=\"CVR Refining eyes $49M saving on biofuels as Trump weighs policy change\" data-tweet=\"$CVRR - CVR Refining eyes $49M saving on biofuels as Trump weighs policy change https://seekingalpha.com/news/3334258-cvr-refining-eyes-49m-saving-on-biofuels-trump-weighs-policy-change?source=tweet\" data-url=\"https://seekingalpha.com/news/3334258-cvr-refining-eyes-49m-saving-on-biofuels-trump-weighs-policy-change\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:26 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3334255\" data-ts=\"1519672380\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AABA\" target=\"_blank\">AABA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3334255-jpmorgan-altaba-call-delve-yahoo-japan-monetization\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">JPMorgan: Altaba call could delve into Yahoo Japan monetization</a></h4><ul>   <li>Altaba (<a href=\"http://seekingalpha.com/symbol/AABA\" target=\"_blank\">AABA</a> <font color='red'>-0.4%</font>) is set to deliver a conference call tomorrow that may give some clarity on a potential timeline for monetizing its Yahoo Japan (<a href=\"http://seekingalpha.com/symbol/YAHOY\" target=\"_blank\">YAHOY</a> <font color='green'>+1.9%</font>) stake, JPMorgan says.</li>    <li>That's more likely now with successful tax reform legislation, analyst Doug Anmuth suggests. There are complex tax-efficient ways to monetize Yahoo Japan, he says, but the most likely outcome is a fully taxed share sale.</li>    <li><a href='https://seekingalpha.com/symbol/AABA' title='Altaba, Inc.'>AABA</a> stock is trading around a 26% discount to its pretax NAV, JPMorgan says.</li>    <li>UBS analyst Eric Sheridan does expect the call will cover tax effects but won't touch Yahoo Japan monetization, Bloomberg's Stephen Sweeney notes.</li>    <li>The call is <a href=\"https://altaba.com/releasedetail.cfm?ReleaseID=1057727\" target=\"_blank\">set for 8:30 a.m. ET</a> tomorrow.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3334255\" data-linked=\"JPMorgan: Altaba call could delve into Yahoo Japan monetization\" data-tweet=\"$AABA $AABA $YAHOY - JPMorgan: Altaba call could delve into Yahoo Japan monetization https://seekingalpha.com/news/3334255-jpmorgan-altaba-call-delve-yahoo-japan-monetization?source=tweet\" data-url=\"https://seekingalpha.com/news/3334255-jpmorgan-altaba-call-delve-yahoo-japan-monetization\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:13 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>126&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3334253\" data-ts=\"1519671877\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BOJA\" target=\"_blank\">BOJA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3334253-bojangles-still-trending-higher\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Bojangles still trending higher</a></h4><ul> <li>Something is going on with Bojangles (<a href='https://seekingalpha.com/symbol/BOJA' title='Bojangles&#39;'>BOJA</a> <font color='green'>+6.1%</font>). Shares have now moved over their 50-day and 100-day moving averages per Bloomberg in a two-week rally tied to M&amp;A speculation.</li> <li>The strong move comes ahead of Bojangles earnings report scheduled for March 6.</li> <li>Bojangles still trades on the low end of its 52-week range of $11.35 to $22.35.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3334253\" data-linked=\"Bojangles still trending higher\" data-tweet=\"$BOJA - Bojangles still trending higher https://seekingalpha.com/news/3334253-bojangles-still-trending-higher?source=tweet\" data-url=\"https://seekingalpha.com/news/3334253-bojangles-still-trending-higher\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:04 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3334252\" data-ts=\"1519671698\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TAHO\" target=\"_blank\">TAHO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3334252-energy-materials-top-gainers-losers-of-2-00-pm-2-26-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Energy/Materials - Top Gainers / Losers as of 2:00 pm (2/26/2018)</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/TAHO' title='Tahoe Resources Inc.'>TAHO</a> <font color='green'>+19%</font>. <a href='https://seekingalpha.com/symbol/IKNX' title='Ikonics Corporation'>IKNX</a> <font color='green'>+14%</font>. <a href='https://seekingalpha.com/symbol/RKDA' title='Arcadia Biosciences'>RKDA</a> <font color='green'>+9%</font>. <a href='https://seekingalpha.com/symbol/ZN' title='Zion Oil & Gas Inc'>ZN</a> <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/ECR' title='Eclipse Resources'>ECR</a> <font color='green'>+8%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/SQM' title='Chemical & Mining Co. of Chile Inc.'>SQM</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/SEMG' title='SemGroup Corporation'>SEMG</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/ALB' title='Albemarle Corporation'>ALB</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/ASIX' title='AdvanSix Inc.'>ASIX</a> <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/ICD' title='Independence Contract Drilling'>ICD</a> <font color='red'>-6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3334252\" data-linked=\"Energy/Materials - Top Gainers / Losers as of 2:00 pm (2/26/2018)\" data-tweet=\"$TAHO $TAHO $IKNX - Energy/Materials - Top Gainers / Losers as of 2:00 pm (2/26/2018) https://seekingalpha.com/news/3334252-energy-materials-top-gainers-losers-of-2-00-pm-2-26-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3334252-energy-materials-top-gainers-losers-of-2-00-pm-2-26-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:01 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>21&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3334250\" data-ts=\"1519671614\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ZSAN\" target=\"_blank\">ZSAN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3334250-zosano-up-big-news-scarce-shares-ahead-95\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Zosano up big but news scarce; shares ahead 95%</a></h4><ul><li>Thinly traded nano cap Zosano Pharma (<a href='https://seekingalpha.com/symbol/ZSAN' title='Zosano Pharma'>ZSAN</a> <font color='green'>+95.3%</font>) is up a healthy 21x surge in volume. No particular news accounts for the action.</li><li>A couple of weeks ago, it filed an <a href=\"https://www.sec.gov/Archives/edgar/data/1587221/000119312518040699/d479354ds1a.htm\" target=\"_blank\">updated prospectus</a> for a public offering of 12.5M shares of common stock.</li><li>At the end of Q3 2017, it had $19.8M in quick assets. Operations consumed $21.0M through the first three quarters of last year.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3295172-zosanos-m207-shows-treatment-effect-late-stage-migraine-study-shares-ahead-19-percent\" target=\"_blank\">Zosano's M207 shows treatment effect in late-stage migraine study; shares ahead 19%</a> (Sept. 13, 2017)</li></ul><div class=\"tiny-share-widget\" data-id=\"3334250\" data-linked=\"Zosano up big but news scarce; shares ahead 95%\" data-tweet=\"$ZSAN - Zosano up big but news scarce; shares ahead 95% https://seekingalpha.com/news/3334250-zosano-up-big-news-scarce-shares-ahead-95?source=tweet\" data-url=\"https://seekingalpha.com/news/3334250-zosano-up-big-news-scarce-shares-ahead-95\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:00 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3334244\" data-ts=\"1519670898\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ADVM\" target=\"_blank\">ADVM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3334244-adverum-progressing-study-of-advmminus-043-in-a1at-deficiency-investors-unmoved-shares-down-4\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Adverum progressing study of ADVM-043 in A1AT deficiency; investors unmoved, shares down 4%</a></h4><ul><li>The independent Data Monitoring Committee has recommended <a href=\"https://seekingalpha.com/pr/17084284-adverum-biotechnologies-announces-completion-dosing-first-cohort-patients-advance-phase-1-2\" target=\"_blank\">proceeding </a>to the second cohort in a Phase 1/2 clinical trial, <a href=\"https://clinicaltrials.gov/ct2/show/NCT02168686?term=nct02168686&amp;rank=1\" target=\"_blank\">ADVANCE</a>, evaluating Adverum Biotechnologies' (<a href='https://seekingalpha.com/symbol/ADVM' title='Adverum Biotechnologies, Inc.'>ADVM</a> <font color='red'>-3.6%</font>) lead candidate ADVM-043 for the treatment of <a href=\"https://ghr.nlm.nih.gov/condition/alpha-1-antitrypsin-deficiency\" target=\"_blank\">alpha-1 antitrypsin (A1AT) deficiency</a>, a rare inherited disorder associated with increased risk of chronic obstructive pulmonary disease, liver disease and skin problems. Preliminary results should be available in H2.</li><li>The DMC's go-ahead was based on safety data generated in the first cohort (n=2) which received a lose dose of the gene therapy.</li><li><a href=\"http://adverum.com/science/\" target=\"_blank\">ADVM-043</a> is designed to induce stable long-term A1AT protein from a single administration.</li></ul><div class=\"tiny-share-widget\" data-id=\"3334244\" data-linked=\"Adverum progressing study of ADVM-043 in A1AT deficiency; investors unmoved, shares down 4%\" data-tweet=\"$ADVM - Adverum progressing study of ADVM-043 in A1AT deficiency; investors unmoved, shares down 4% https://seekingalpha.com/news/3334244-adverum-progressing-study-of-advmminus-043-in-a1at-deficiency-investors-unmoved-shares-down-4?source=tweet\" data-url=\"https://seekingalpha.com/news/3334244-adverum-progressing-study-of-advmminus-043-in-a1at-deficiency-investors-unmoved-shares-down-4\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:48 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3334246\" data-ts=\"1519670846\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NCMI\" target=\"_blank\">NCMI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3334246-national-cinemediaplus-6_2-on-heavy-volume\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">National CineMedia +6.2% on heavy volume</a></h4><ul>   <li>Heavy volume that arrived around 10:45 has lifted shares of theatrical advertising firm National CineMedia (<a href=\"http://seekingalpha.com/symbol/NCMI\" target=\"_blank\">NCMI</a> <font color='green'>+6.2%</font>), which has hit its highest point since last May.</li>    <li>More than 1M shares have changed hands vs. a typical daily average of less than 500K.</li>    <li>There's no single catalyst for the move, though the company this week rolled out a new augmented reality app (Noovie ARcade) to go along with its revamped film preshow.</li>    <li>The company's also likely riding some of the record success of Marvel's <i>Black Panther;</i> NCMI <a href=\"https://seekingalpha.com/news/3298025-disney-behind-scenes-content-headed-movie-pre-shows\" target=\"_blank\">partnered with Marvel parent Disney</a> in the fall on a deal that sends exclusive behind-the-scenes footage to preshows for key Disney releases including <i>Coco, Solo, Avengers: Infinity War</i> and <i>Black Panther.</i></li> </ul><div class=\"tiny-share-widget\" data-id=\"3334246\" data-linked=\"National CineMedia +6.2% on heavy volume\" data-tweet=\"$NCMI - National CineMedia +6.2% on heavy volume https://seekingalpha.com/news/3334246-national-cinemediaplus-6_2-on-heavy-volume?source=tweet\" data-url=\"https://seekingalpha.com/news/3334246-national-cinemediaplus-6_2-on-heavy-volume\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:47 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3334245\" data-ts=\"1519670821\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/QCOM\" target=\"_blank\">QCOM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3334245-ft-qualcomm-wants-over-90-share-from-broadcom\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FT: Qualcomm wants over $90/share from Broadcom</a></h4><ul><li>        Qualcomm (NASDAQ:<a href='https://seekingalpha.com/symbol/QCOM' title='Qualcomm Inc.'>QCOM</a>) would agree to Broadcom&rsquo;s (NASDAQ:<a href='https://seekingalpha.com/symbol/AVGO' title='Broadcom Limited'>AVGO</a>) acquisition offer if the price were raised to $160B (including $25B in debt), which equals out to above $90/share, according to <a href=\"https://www.ft.com/content/c3134324-1b17-11e8-aaca-4574d7dabfb6\" target=\"_blank\">FT sources</a>.&nbsp;</li><li>               Broadcom is currently offering $79 per share ($142B), so Qualcomm wants at least 15% more.&nbsp;</li><li>               Sources say Broadcom has made enough progress in addressing potential antitrust issues that the talks have shifted to price negotiations.&nbsp;</li><li>               Broadcom calls Qualcomm&rsquo;s price talks &ldquo;engagement theatre&rdquo; and says it doesn&rsquo;t believe the letter released earlier today was &ldquo;designed to lead to a prompt agreement.&rdquo;&nbsp;</li><li>               Qualcomm shares are&nbsp;<font color='green'>up 4.3%</font>.&nbsp;</li><li>Broadcom shares are&nbsp;<font color='red'>down 0.5%</font>.&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3334051-qualcomm-broadcom-met-still-stuck-price\" target=\"_blank\">Qualcomm and Broadcom met again, still stuck on price</a> (Feb. 26)</li></ul><div class=\"tiny-share-widget\" data-id=\"3334245\" data-linked=\"FT: Qualcomm wants over $90/share from Broadcom\" data-tweet=\"$QCOM $QCOM $AVGO - FT: Qualcomm wants over $90/share from Broadcom https://seekingalpha.com/news/3334245-ft-qualcomm-wants-over-90-share-from-broadcom?source=tweet\" data-url=\"https://seekingalpha.com/news/3334245-ft-qualcomm-wants-over-90-share-from-broadcom\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:47 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>177&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3334243\" data-ts=\"1519670369\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HMNY\" target=\"_blank\">HMNY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3334243-helios-and-matheson-higher-amid-black-panther-phenomenon\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Helios and Matheson higher amid Black Panther phenomenon</a></h4><ul> <li>Helios and Matheson Analytics (NASDAQ:<a href='https://seekingalpha.com/symbol/HMNY' title='Helios and Matheson Analytics, Inc.'>HMNY</a>) is&nbsp;<font color='green'>up 3.65%</font>&nbsp;to $5.11 on what's been a strong day for movie theater stocks.</li> <li>There's still a lot to unpack with the MoviePass business model as the company is seemingly on the financial hook after attendance rises like over the last two weekends. On the flip side, you have Canaccord Genuity issuing a price target of $15 and explaining in great detail how MoviePass' explosive growth will lead to huge leverage opportunities down the road (think Priceline.com).</li><li>There's also quite of trading on HMNY based off the stock's volatility, and not its business model or fundamentals.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3334228-black-panther-provides-another-lift-theater-sector\" target=\"_blank\">Black Panther provides another lift to theater sector</a> (Feb. 26)</li>   </ul><div class=\"tiny-share-widget\" data-id=\"3334243\" data-linked=\"Helios and Matheson higher amid Black Panther phenomenon\" data-tweet=\"$HMNY - Helios and Matheson higher amid Black Panther phenomenon https://seekingalpha.com/news/3334243-helios-and-matheson-higher-amid-black-panther-phenomenon?source=tweet\" data-url=\"https://seekingalpha.com/news/3334243-helios-and-matheson-higher-amid-black-panther-phenomenon\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:39 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>50&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3334242\" data-ts=\"1519669359\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AAPL\" target=\"_blank\">AAPL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3334242-bloomberg-apple-releasing-three-iphones-this-fall\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Bloomberg: Apple releasing three iPhones this fall</a></h4><ul><li>        Apple (NASDAQ:<a href='https://seekingalpha.com/symbol/AAPL' title='Apple Inc.'>AAPL</a>) will release three new iPhones this fall, according to <a href=\"https://www.bloomberg.com/news/articles/2018-02-26/apple-is-said-to-plan-giant-high-end-iphone-lower-priced-model\" target=\"_blank\">Bloomberg sources</a>.</li><li>               The lineup will include the largest iPhone ever (close to a 6.5-inch screen), a lower cost version of the iPhone X, and a budget-friendly option that doesn&rsquo;t skimp on the features.&nbsp;&nbsp;</li><li>               The large, phablet iPhone could have a screen resolution of 1242 x 2688 and will include an OLED panel and Face ID like the X.&nbsp;</li><li>               The phablet and the smaller, updated iPhone X version will both have next-gen A12 processors and stainless steel edges.&nbsp;</li><li>               Apple is considering a dual-SIM card option for the larger model, which could sell well in Europe and Asia where customers travel between countries more frequently.&nbsp;</li><li>                  The third, lower cost version will have an edge-to-edge screen and Face ID like the X but a cheaper LCD screen, aluminum edges, and a glass back.    </li><li>               Apple sold 77.3M iPhones in Q4 of CY17 compared to the 80.2M expected by analysts.&nbsp;&nbsp;</li><li>               Apple shares are&nbsp;<font color='green'>up 1.9%</font>.&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3334187-apple-confirms-using-google-cloud-cook-will-co-chair-china-business-forum\" target=\"_blank\">Apple confirms using Google Cloud; Cook will co-chair China business forum</a> (Feb. 26)</li></ul><div class=\"tiny-share-widget\" data-id=\"3334242\" data-linked=\"Bloomberg: Apple releasing three iPhones this fall\" data-tweet=\"$AAPL - Bloomberg: Apple releasing three iPhones this fall https://seekingalpha.com/news/3334242-bloomberg-apple-releasing-three-iphones-this-fall?source=tweet\" data-url=\"https://seekingalpha.com/news/3334242-bloomberg-apple-releasing-three-iphones-this-fall\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:22 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>43&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3334240\" data-ts=\"1519668976\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NFLX\" target=\"_blank\">NFLX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3334240-netflix-300-watch-is-on\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">The Netflix $300 watch is on</a></h4><ul> <li>Netflix (NASDAQ:<a href='https://seekingalpha.com/symbol/NFLX' title='Netflix, Inc.'>NFLX</a>) is&nbsp;<font color='green'>up 2.39%</font>&nbsp;on the day and pushed to as high as $295.59 earlier in the day as the watch for <strong>$300</strong> gets a little more serious.</li><li>Just short of 7M shares of Netflix have traded today vs. the daily average of 8.59M shares.</li> <li>While there's no question that the multi-year run for Netflix has been dizzying, SA contributor Ziyaad Manie laid out the <a href=\"https://seekingalpha.com/article/4148133-netflix-still-undervalued\" target=\"_blank\">case</a> last week as to why the rally makes sense based off of long-term subscriber growth estimates and higher pricing</li>   </ul><div class=\"tiny-share-widget\" data-id=\"3334240\" data-linked=\"The Netflix $300 watch is on\" data-tweet=\"$NFLX - The Netflix $300 watch is on https://seekingalpha.com/news/3334240-netflix-300-watch-is-on?source=tweet\" data-url=\"https://seekingalpha.com/news/3334240-netflix-300-watch-is-on\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:16 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>28&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3334211\" data-ts=\"1519668083\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GS\" target=\"_blank\">GS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3334211-big-trading-days-goldman-fell-in-2017\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Big trading days at Goldman fell in 2017</a></h4><ul><li>Days in which Goldman Sachs (NYSE:<a href='https://seekingalpha.com/symbol/GS' title='Goldman Sachs Group Inc.'>GS</a>) <a href=\"https://www.bloomberg.com/news/articles/2018-02-26/goldman-s-big-trading-days-dropped-to-lowest-last-year-since-04\" target=\"_blank\">made more than $100M in trading revenue</a> fell to four in 2017, the lowest since 2009 when the firm had 131 high-revenue trading days.</li><li><a href=\"http://www.goldmansachs.com/investor-relations/financials/\" target=\"_blank\">The company's annual report </a>states VaR lower across all asset classes with daily market risk in currency trading dropping to $12M.</li><li>The investment bank says competitive pressure has compressed bid-offer spreads hurting trading revenue.</li></ul><div class=\"tiny-share-widget\" data-id=\"3334211\" data-linked=\"Big trading days at Goldman fell in 2017\" data-tweet=\"$GS - Big trading days at Goldman fell in 2017 https://seekingalpha.com/news/3334211-big-trading-days-goldman-fell-in-2017?source=tweet\" data-url=\"https://seekingalpha.com/news/3334211-big-trading-days-goldman-fell-in-2017\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:01 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3334237\" data-ts=\"1519668042\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FRSX\" target=\"_blank\">FRSX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3334237-financials-top-5-gainers-losers-of-1-00-pm-02-26-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Financials - Top 5 Gainers / Losers as of 1:00 PM (02/26/2018)</a></h4><ul><li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/FRSX' title='Foresight Autonomous Holdings Ltd.'>FRSX</a> <font color='green'>+11%</font>. <a href='https://seekingalpha.com/symbol/NKSH' title='National Bankshares, Inc.'>NKSH</a> <font color='green'>+8%</font>.<a href='https://seekingalpha.com/symbol/SAMG' title='Silvercrest Asset Management Group'>SAMG</a> <font color='green'>+5%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/MLP' title='Maui Land & Pineapple Company, Inc.'>MLP</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/CIFS' title='China Internet Nationwide Financial Services Inc.'>CIFS</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/GOV-OLD' title='Government Properties Income Trust'>GOV-OLD</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/CLDT' title='Chatham Lodging Trust'>CLDT</a> <font color='red'>-7%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3334237\" data-linked=\"Financials - Top 5 Gainers / Losers as of 1:00 PM (02/26/2018)\" data-tweet=\"$FRSX $FRSX $NKSH - Financials - Top 5 Gainers / Losers as of 1:00 PM (02/26/2018) https://seekingalpha.com/news/3334237-financials-top-5-gainers-losers-of-1-00-pm-02-26-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3334237-financials-top-5-gainers-losers-of-1-00-pm-02-26-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:00 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3334235\" data-ts=\"1519667883\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GE\" target=\"_blank\">GE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3334235-ges-latest-troubles-knock-shares-back-analysts-cite-litany-of-liabilities\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">GE&#39;s latest troubles knock shares back further; analysts cite &#39;litany of liabilities&#39;</a></h4><ul>     <li>General Electric (<a href='https://seekingalpha.com/symbol/GE' title='General Electric'>GE</a> <font color='red'>-1.8%</font>) tumbles as much as 3.7% to a new 52-week low after revealing plans to <a href=\"https://seekingalpha.com/news/3334011-ge-restate-two-years-earnings\" target=\"_blank\">restate earnings for 2016 and 2017</a> to reflect a new accounting standard, disclosing an <a href=\"https://seekingalpha.com/news/3333987-ge-says-face-doj-action-subprime-mortgage-operations\" target=\"_blank\">investigation into subprime mortgage loans</a> made before the financial crisis, and <a href=\"https://seekingalpha.com/news/3334053-ge-nominates-three-new-board-directors\" target=\"_blank\">making changes to its board</a>.</li>     <li>J.P. Morgan analyst Stephen Tusa maintains his Underweight rating on GE and Deutsche Bank's John Inch keeps his Sell rating and $13 price target, saying the company is vulnerable to contingent liability risks.</li>     <li>Vertical Research's Jeff Sprague reiterates a Hold rating, saying GE faces a \"<a href=\"https://www.barrons.com/articles/general-electric-keeps-finding-ways-to-hit-new-lows-1519665047\" target=\"_blank\">litany of liabilities</a>,\" and estimating GE Industrial's leverage is at 3.2x his 2018 EBITDA estimate and that GE Capital may not be able to fully fund its legacy liabilities without support from GE.</li>     <li>CEO&nbsp;John Flannery sends a letter to shareholder acknowledging \"a very tough year\" in 2017 while <a href=\"https://www.bloomberg.com/news/articles/2018-02-26/ge-tumbles-again-as-past-missteps-weigh-on-ceo-s-turnaround-bid\" target=\"_blank\">defending the company</a>, saying &ldquo;How [GE] is being portrayed in certain quarters is overwrought and, in most cases, does not reflect the reality of GE that our customers and employees are seeing around the world. There are things we need to fix. But we can. We know how to. And we will.&rdquo;</li> </ul><div class=\"tiny-share-widget\" data-id=\"3334235\" data-linked=\"GE&#39;s latest troubles knock shares back further; analysts cite &#39;litany of liabilities&#39;\" data-tweet=\"$GE - GE&#39;s latest troubles knock shares back further; analysts cite &#39;litany of liabilities&#39; https://seekingalpha.com/news/3334235-ges-latest-troubles-knock-shares-back-analysts-cite-litany-of-liabilities?source=tweet\" data-url=\"https://seekingalpha.com/news/3334235-ges-latest-troubles-knock-shares-back-analysts-cite-litany-of-liabilities\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:58 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>51&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3334233\" data-ts=\"1519667819\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MACK\" target=\"_blank\">MACK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3334233-mid-stage-study-underway-on-merrimacks-seribantumab-in-breast-cancer-shares-up-1\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Mid-stage study underway on Merrimack&#39;s seribantumab in breast cancer; shares up 1%</a></h4><ul><li>The first patient has been <a href=\"https://seekingalpha.com/pr/17083824-merrimack-doses-first-patient-randomized-phase-2-clinical-study-mmminus-121-patients-post\" target=\"_blank\">dosed </a>in a <a href=\"https://clinicaltrials.gov/ct2/show/NCT03241810?intr=mm-121&amp;spons=merrimack&amp;phase=1&amp;rank=5\" target=\"_blank\">Phase 2 clinical trial</a> evaluating Merrimack Pharmaceuticals' (<a href='https://seekingalpha.com/symbol/MACK' title='Merrimack Pharmaceuticals'>MACK</a> <font color='green'>+1.4%</font>) MM-121 (seribantumab) in patients with heregulin-positive, hormone receptor-positive, HER2-negative postmenopausal metastatic breast cancer.</li><li>The randomized study will assess the combination of seribantumab and fulvestrant (AstraZeneca's <a href=\"https://www.faslodex.com/?source=FAS_D_C_14&amp;umedium=CPC&amp;uadpub=Google&amp;ucampaign=FaslodexDTCBranded_General&amp;ucreative=Branded_Alone_EX&amp;uplace=fulvestrant&amp;cmpid=1\" target=\"_blank\">FASLODEX</a>) compared to fulvestrant + placebo. The primary endpoint is progression-free survival &#40;PFS&#41; at month 20. The estimated primary completion date is April 2019.</li><li>Heregulin is a secreted growth factor that is associated with cell proliferation, invasion, survival and differentiation in certain malignancies.</li><li>Seribantumab is a fully human monoclonal antibody that binds to a receptor on tumor cells called&nbsp;<a href=\"https://en.wikipedia.org/wiki/ERBB3\" target=\"_blank\">ErbB3</a>, which is activated by&nbsp;<a href=\"http://mcr.aacrjournals.org/content/1/3/165.full\" target=\"_blank\">heregulin</a>. ErbB3 signaling is thought to play a key role in tumor growth and resistance to cytotoxic and anti-endocrine therapies. Seribantumab blocks ErbB3 signaling which enhances the anti-tumor effect of the combination therapy.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3305537-merrimacks-mmminus-121-orphan-drug-u-s-heregulin-positive-non-small-cell-lung-cancer-shares\" target=\"_blank\">Merrimack's MM-121 an Orphan Drug in U.S. for heregulin-positive non-small cell lung cancer; shares ahead 5% premarket</a> (Oct. 30, 2017)</li></ul><div class=\"tiny-share-widget\" data-id=\"3334233\" data-linked=\"Mid-stage study underway on Merrimack&#39;s seribantumab in breast cancer; shares up 1%\" data-tweet=\"$MACK - Mid-stage study underway on Merrimack&#39;s seribantumab in breast cancer; shares up 1% https://seekingalpha.com/news/3334233-mid-stage-study-underway-on-merrimacks-seribantumab-in-breast-cancer-shares-up-1?source=tweet\" data-url=\"https://seekingalpha.com/news/3334233-mid-stage-study-underway-on-merrimacks-seribantumab-in-breast-cancer-shares-up-1\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:56 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3334229\" data-ts=\"1519667398\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NXTD\" target=\"_blank\">NXTD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3334229-midday-gainers-losers-2-26-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Midday Gainers / Losers (2/26/2018)</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/NXTD' title='NXT-ID Inc.'>NXTD</a> <font color='green'>+30%</font>. <a href='https://seekingalpha.com/symbol/TAHO' title='Tahoe Resources Inc.'>TAHO</a> <font color='green'>+20%</font>. <a href='https://seekingalpha.com/symbol/RCM' title='R1 RCM Inc.'>RCM</a> <font color='green'>+20%</font>. <a href='https://seekingalpha.com/symbol/ZSAN' title='Zosano Pharma'>ZSAN</a> <font color='green'>+18%</font>. <a href='https://seekingalpha.com/symbol/TTPH' title='Tetraphase Pharmaceuticals'>TTPH</a> <font color='green'>+18%</font>. <a href='https://seekingalpha.com/symbol/APLS' title='Apellis Pharmaceuticals, Inc.'>APLS</a> <font color='green'>+16%</font>. <a href='https://seekingalpha.com/symbol/XTNT' title='Xtant Medical Holdings, Inc.'>XTNT</a> <font color='green'>+15%</font>. <a href='https://seekingalpha.com/symbol/DTRM' title='Determine, Inc.'>OTC:DTRM</a> <font color='green'>+14%</font>. <a href='https://seekingalpha.com/symbol/CGEN' title='Compugen Ltd.'>CGEN</a> <font color='green'>+14%</font>. <a href='https://seekingalpha.com/symbol/ACHN' title='Achillion Pharmaceuticals, Inc.'>ACHN</a> <font color='green'>+14%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/ABIO' title='ARCA biopharma, Inc.'>ABIO</a> <font color='red'>-70%</font>. <a href='https://seekingalpha.com/symbol/IRIX' title='IRIDEX Corporation'>IRIX</a> <font color='red'>-17%</font>. <a href='https://seekingalpha.com/symbol/IFRX' title='InflaRx N.V.'>IFRX</a> <font color='red'>-16%</font>. <a href='https://seekingalpha.com/symbol/DF' title='Dean Foods Company'>DF</a> <font color='red'>-14%</font>. <a href='https://seekingalpha.com/symbol/I' title='Intelsat SA'>I</a> <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/MDXG' title='MiMedx Group Inc.'>OTC:MDXG</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/MYSZ' title='MySize Inc.'>MYSZ</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/SQM' title='Chemical & Mining Co. of Chile Inc.'>SQM</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/MLP' title='Maui Land & Pineapple Company, Inc.'>MLP</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/QBAK' title='Qualstar Corporation'>QBAK</a> <font color='red'>-9%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3334229\" data-linked=\"Midday Gainers / Losers (2/26/2018)\" data-tweet=\"$NXTD $NXTD $TAHO - Midday Gainers / Losers (2/26/2018) https://seekingalpha.com/news/3334229-midday-gainers-losers-2-26-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3334229-midday-gainers-losers-2-26-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:49 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3334228\" data-ts=\"1519667122\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RGC\" target=\"_blank\">RGC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3334228-black-panther-provides-another-lift-to-theater-sector\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Black Panther provides another lift to theater sector</a></h4><ul> <li>Exhibitor stocks are in the sights of investors again after <em>Black Panther</em> put in a very solid second weekend at the U.S. box office.</li> <li>The Disney film brought in $108M to easily outdistance second place <em>Game Night</em> with its $16.6M opening weekend haul.</li> <li>Thanks largely to the last two monster weekends from <em>Black Panther</em>, the YTD <a href=\"http://www.boxofficemojo.com/yearly/?view2=ytdcompare&amp;view=releasedate&amp;p=.htm\" target=\"_blank\">U.S. box office</a> total is 14% higher through February 25 than a year ago.</li><li>Regal Entertainment (<a href='https://seekingalpha.com/symbol/RGC' title='Regal Entertainment Group'>RGC</a>), AMC Entertainment (<a href='https://seekingalpha.com/symbol/AMC' title='AMC Entertainment Holdings, Inc'>AMC</a> <font color='green'>+6.4%</font>), Cinemark Holdings (<a href='https://seekingalpha.com/symbol/CNK' title='Cinemark Holdings, Inc'>CNK</a> <font color='green'>+2.4%</font>), Reading International (<a href='https://seekingalpha.com/symbol/RDI' title='Reading International, Inc.'>RDI</a> <font color='green'>+1%</font>).</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3334228\" data-linked=\"Black Panther provides another lift to theater sector\" data-tweet=\"$RGC $RGC $AMC - Black Panther provides another lift to theater sector https://seekingalpha.com/news/3334228-black-panther-provides-another-lift-to-theater-sector?source=tweet\" data-url=\"https://seekingalpha.com/news/3334228-black-panther-provides-another-lift-to-theater-sector\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:45 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3334225\" data-ts=\"1519666300\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ATBPF\" target=\"_blank\">ATBPF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3334225-antibe-to-report-preliminary-mid-stage-data-on-atbminus-346-next-month-shares-up-2\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Antibe to report preliminary mid-stage data on ATB-346 next month; shares up 2%</a></h4><ul><li>Thinly traded nano cap Antibe Therapeutics (<a href='https://seekingalpha.com/symbol/ATBPF' title='Antibe Therapeutics, Inc.'>OTCQB:ATBPF</a> <font color='green'>+2%</font>) is up on almost triple normal volume, albeit on turnover of only 161K shares, on the heels of its <a href=\"https://seekingalpha.com/pr/17083857-antibe-therapeutics-provides-update-phase-2b-gastrointestinal-safety-study-lead-pain-drug\" target=\"_blank\">announcement </a>that it expects to report topline data from a Phase 2b clinical trial assessing lead candidate ATB-346 compared to naproxen during the week of March 19.</li><li>ATB-346 is a hydrogen sulfide-releasing derivative of the NSAID pain med naproxen designed to deliver a better safety profile. NSAIDs (nonsteroidal anti-inflammatory drugs) are used to treat pain and inflammation, but they are associated with a high rate of GI ulceration and bleeding.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3325968-antibe-completes-enrollment-mid-stage-safety-study-lead-candidate-atbminus-346\" target=\"_blank\">Antibe completes enrollment in mid-stage safety study of lead candidate ATB-346</a> (Jan. 29)</li></ul><div class=\"tiny-share-widget\" data-id=\"3334225\" data-linked=\"Antibe to report preliminary mid-stage data on ATB-346 next month; shares up 2%\" data-tweet=\"$ATBPF - Antibe to report preliminary mid-stage data on ATB-346 next month; shares up 2% https://seekingalpha.com/news/3334225-antibe-to-report-preliminary-mid-stage-data-on-atbminus-346-next-month-shares-up-2?source=tweet\" data-url=\"https://seekingalpha.com/news/3334225-antibe-to-report-preliminary-mid-stage-data-on-atbminus-346-next-month-shares-up-2\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:31 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3334221\" data-ts=\"1519665546\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NEOS\" target=\"_blank\">NEOS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3334221-neos-launches-adzenys-er-in-u-s-shares-up-1\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Neos launches Adzenys ER in U.S.; shares up 1%</a></h4><ul><li>Neos Therapeutics (<a href='https://seekingalpha.com/symbol/NEOS' title='Neos Therapeutics'>NEOS</a> <font color='green'>+1.1%</font>) <a href=\"https://seekingalpha.com/pr/17083997-neos-therapeutics-launches-adzenys-er-amphetamine-extended-release-oral-suspension-u-s\" target=\"_blank\">commences </a>the U.S. commercial launch of Adzenys ER (amphetamine) Extended-Release Oral Suspension for the treatment of attention deficit hyperactivity disorder. The FDA approved it about five months ago.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3295899-neos-therapeutics-sells-despite-latest-fda-approval\" target=\"_blank\">Neos Therapeutics sells off despite latest FDA approval</a> (Sept. 15, 2017)</li></ul><div class=\"tiny-share-widget\" data-id=\"3334221\" data-linked=\"Neos launches Adzenys ER in U.S.; shares up 1%\" data-tweet=\"$NEOS - Neos launches Adzenys ER in U.S.; shares up 1% https://seekingalpha.com/news/3334221-neos-launches-adzenys-er-in-u-s-shares-up-1?source=tweet\" data-url=\"https://seekingalpha.com/news/3334221-neos-launches-adzenys-er-in-u-s-shares-up-1\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:19 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3334219\" data-ts=\"1519665198\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VRAY\" target=\"_blank\">VRAY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3334219-viewray-secures-59m-private-capital-raise-shares-up-1\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">ViewRay secures $59M private capital raise; shares up 1%</a></h4><ul><li>ViewRay (<a href='https://seekingalpha.com/symbol/VRAY' title='ViewRay'>VRAY</a> <font color='green'>+1.2%</font>) inks an <a href=\"https://seekingalpha.com/pr/17084143-viewray-announces-59-million-equity-financing\" target=\"_blank\">agreement </a>with an affiliate of Fosun International Limited for the direct sale of stock and warrants yielding ~$59.1M in gross proceeds.</li><li>Specifically, the company will sell Fosun ~7.1M shares of common stock and warrants to purchase up to ~1.4M shares of common at $8.31.</li><li>The transaction will boost Fosun's stake in the company to 18.4% from 9.9%. Closing date is March 2.</li></ul><div class=\"tiny-share-widget\" data-id=\"3334219\" data-linked=\"ViewRay secures $59M private capital raise; shares up 1%\" data-tweet=\"$VRAY - ViewRay secures $59M private capital raise; shares up 1% https://seekingalpha.com/news/3334219-viewray-secures-59m-private-capital-raise-shares-up-1?source=tweet\" data-url=\"https://seekingalpha.com/news/3334219-viewray-secures-59m-private-capital-raise-shares-up-1\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:13 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3334216\" data-ts=\"1519664553\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SQBG\" target=\"_blank\">SQBG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3334216-consumer-top-gainers-losers-of-12-00-pm-2-26-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Consumer - Top Gainers / Losers as of 12:00 pm (2/26/2018)</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/SQBG' title='Sequential Brands Group, Inc.'>SQBG</a> <font color='green'>+7%</font>. <a href='https://seekingalpha.com/symbol/THO' title='Thor Industries, Inc.'>THO</a> <font color='green'>+6%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/DF' title='Dean Foods Company'>DF</a> <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/UEIC' title='Universal Electronics Inc.'>UEIC</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/FTFT' title='Future Fintech Group Inc'>FTFT</a> <font color='red'>-6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3334216\" data-linked=\"Consumer - Top Gainers / Losers as of 12:00 pm (2/26/2018)\" data-tweet=\"$SQBG $SQBG $THO - Consumer - Top Gainers / Losers as of 12:00 pm (2/26/2018) https://seekingalpha.com/news/3334216-consumer-top-gainers-losers-of-12-00-pm-2-26-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3334216-consumer-top-gainers-losers-of-12-00-pm-2-26-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:02 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3334213\" data-ts=\"1519664431\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DRRX\" target=\"_blank\">DRRX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3334213-mid-stage-study-underway-assessing-durects-durminus-928-in-psc-shares-up-2\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Mid-stage study underway assessing DURECT&#39;s DUR-928 in PSC; shares up 2%</a></h4><ul><li><a href=\"https://seekingalpha.com/pr/17084030-durect-announces-patient-dosing-phase-2a-trial-durminus-928-primary-sclerosing-cholangitis\" target=\"_blank\">Dosing is underway</a> in a Phase 2a clinical trial evaluating DURECT's (<a href='https://seekingalpha.com/symbol/DRRX' title='Durect Corporation'>DRRX</a> <font color='green'>+1.8%</font>) lead candidate DUR-928 in patients with <a href=\"https://emedicine.medscape.com/article/187724-overview\" target=\"_blank\">primary sclerosing cholangitis</a> &#40;PSC&#41;, a chronic liver disorder characterized by progressive inflammation and fibrosis (scarring) in the bile ducts.</li><li>The co-primary endpoints of the open-label study are safety and the percent change from baseline in serum <a href=\"https://www.webmd.com/a-to-z-guides/alkaline_phosphatase_test#1\" target=\"_blank\">alkaline phosphatase</a>, an enzyme that serves as a biomarker for liver or bone disease.</li><li>According to ClinicalTrials.gov, the estimated completion date is January 2019.</li><li><a href=\"http://www.durect.com/wt/durect/page_name/DUR-928\" target=\"_blank\">DUR-928</a>&nbsp;is&nbsp;a small molecule drug that modulates the activity of various nuclear receptors involved in liver&nbsp;<a href=\"http://www.britannica.com/EBchecked/topic/270188/homeostasis\" target=\"_blank\">homeostasis&nbsp;</a>(stable function). It is under development for the potential treatment of nonalcoholic fatty liver disease &#40;NAFLD&#41; and non-alcoholic steatohepatitis &#40;NASH&#41;.</li></ul><div class=\"tiny-share-widget\" data-id=\"3334213\" data-linked=\"Mid-stage study underway assessing DURECT&#39;s DUR-928 in PSC; shares up 2%\" data-tweet=\"$DRRX - Mid-stage study underway assessing DURECT&#39;s DUR-928 in PSC; shares up 2% https://seekingalpha.com/news/3334213-mid-stage-study-underway-assessing-durects-durminus-928-in-psc-shares-up-2?source=tweet\" data-url=\"https://seekingalpha.com/news/3334213-mid-stage-study-underway-assessing-durects-durminus-928-in-psc-shares-up-2\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:00 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3334214\" data-ts=\"1519664422\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IRDM\" target=\"_blank\">IRDM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3334214-iridium-converting-1m-series-preferred-shares-to-common-stock\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Iridium converting 1M Series A preferred shares to common stock</a></h4><ul>   <li>Iridium Communications (<a href=\"http://seekingalpha.com/symbol/IRDM\" target=\"_blank\">IRDM</a> <font color='red'>-3.2%</font>) says it will convert all 1M shares of Series A preferred stock to common shares.</li>    <li>In a <a href=\"https://seekingalpha.com/filing/3902821\" target=\"_blank\">filing</a>, the company notes that Friday marked the 20th trading day out of 30 where its common stock had a volume-weighted average price above $12.16, marking a triggering event for the conversion.</li>    <li>On a March 20 conversion date, holders of that preferred stock will be able to receive 10.6022 shares of common stock for each preferred share, implying a conversion price of $9.432/share. Iridium shares are at $12 currently.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3334214\" data-linked=\"Iridium converting 1M Series A preferred shares to common stock\" data-tweet=\"$IRDM - Iridium converting 1M Series A preferred shares to common stock https://seekingalpha.com/news/3334214-iridium-converting-1m-series-preferred-shares-to-common-stock?source=tweet\" data-url=\"https://seekingalpha.com/news/3334214-iridium-converting-1m-series-preferred-shares-to-common-stock\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:00 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3334212\" data-ts=\"1519664177\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CRK\" target=\"_blank\">CRK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3334212-comstock-resourcesplus-4-higher-prices-boost-nat-gas-sales\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Comstock Resources +4% as higher prices boost nat gas sales</a></h4><ul>     <li>Comstock Resources (<a href='https://seekingalpha.com/symbol/CRK' title='Comstock Resources Inc.'>CRK</a> <font color='green'>+4.2%</font>) is higher after reporting a much smaller than expected <a href=\"https://seekingalpha.com/news/3334047-comstock-resources-beats-0_57-beats-revenue\" target=\"_blank\">Q4 loss</a> and a 51% Y/Y revenue gain.</li>     <li>CRK says it produced 22B cf of natural gas, or 241M cf/day, during Q4, up 90% Y/Y from year-ago pro forma natural gas production, driven by its successful Haynesville shale drilling program.</li>     <li>CRK's Q4 average realized natural gas price, including hedging gains, rose 3% Y/Y to $2.94/Mcf from $2.85 a year earlier, and its average realized oil price gained 23% to $56.48/bbl from $45.96, which caused oil and gas sales to increase 59% to $77.3M from $48.5M in the year-ago quarter.</li>     <li>For FY 2017, CRK's natural gas production of 201M cf/day was a 46% Y/Y increase vs. pro forma 2016 natural gas production, and average realized natural gas price, including hedging gains, jumped 28% to $2.97/Mcf from $2.32 in the previous year.</li></ul><div class=\"tiny-share-widget\" data-id=\"3334212\" data-linked=\"Comstock Resources +4% as higher prices boost nat gas sales\" data-tweet=\"$CRK - Comstock Resources +4% as higher prices boost nat gas sales https://seekingalpha.com/news/3334212-comstock-resourcesplus-4-higher-prices-boost-nat-gas-sales?source=tweet\" data-url=\"https://seekingalpha.com/news/3334212-comstock-resourcesplus-4-higher-prices-boost-nat-gas-sales\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:56 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3334205\" data-ts=\"1519663387\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RCAR\" target=\"_blank\">RCAR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3334205-renovacare-moves-to-pink-sheet-trading-shares-down-33\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">RenovaCare moves to pink sheet trading; shares down 33%</a></h4><ul><li>Thinly traded micro cap RenovaCare (<a href='https://seekingalpha.com/symbol/RCAR' title='RenovaCare, Inc.'>OTCPK:RCAR</a> <font color='red'>-33.1%</font>) slumps on almost triple normal in apparent to response to trading being <a href=\"https://twitter.com/investorsbeware/status/968160959952048130\" target=\"_blank\">transitioned </a>to the OTC pink sheets effective immediately.</li><li>Kudos to The Street Sweeper for the heads up.</li></ul><div class=\"tiny-share-widget\" data-id=\"3334205\" data-linked=\"RenovaCare moves to pink sheet trading; shares down 33%\" data-tweet=\"$RCAR - RenovaCare moves to pink sheet trading; shares down 33% https://seekingalpha.com/news/3334205-renovacare-moves-to-pink-sheet-trading-shares-down-33?source=tweet\" data-url=\"https://seekingalpha.com/news/3334205-renovacare-moves-to-pink-sheet-trading-shares-down-33\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:43 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3334203\" data-ts=\"1519663141\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/I\" target=\"_blank\">I</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3334203-intelsatminus-11_9-on-mixed-q4-low-2018-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Intelsat -11.9% on mixed Q4, low 2018 guidance</a></h4><ul>   <li>Intelsat (NYSE:<a href='https://seekingalpha.com/symbol/I' title='Intelsat SA'>I</a>) is <font color='red'>11.9% lower</font> after <a href=\"https://seekingalpha.com/news/3334039-intelsat-misses-0_49-beats-revenue\" target=\"_blank\">Q4 earnings</a> where revenues fell (but beat consensus) and 2018 guidance came up light.</li>    <li>Net loss came to $90M vs. a year-ago gain of $662.8M (which was boosted by a $679.1M gain on extinguishment of debt).</li>    <li>Revenues declined across each customer set.</li>    <li>Adjusted EBITDA came to $416.4M (77% of revenue)</li>    <li>Revenue by customer set: Network Services, $212.2M (down 4.4%); Media, $226.2M (down 0.9%); Government, $90.1M (down 3.3%); Other, $9.6M (up 33.2%).</li>    <li>Free cash flow used in operations was $35.4M for the quarter.</li>    <li>For 2018, it's guiding to revenue of $2.06B-$2.11B (light of consensus for $2.13B) and EBITDA of $1.56B-$1.605B (below an expected $1.625B). It sees the media business stable to a 3% decline in revenues; network services declining 5-8%; and government business revenue growth ranging from -1% to 2%.</li>    <li><a href=\"https://seekingalpha.com/pr/17083807-intelsat-announces-fourth-quarter-full-year-2017-results\" target=\"_blank\">Press release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3334203\" data-linked=\"Intelsat -11.9% on mixed Q4, low 2018 guidance\" data-tweet=\"$I - Intelsat -11.9% on mixed Q4, low 2018 guidance https://seekingalpha.com/news/3334203-intelsatminus-11_9-on-mixed-q4-low-2018-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3334203-intelsatminus-11_9-on-mixed-q4-low-2018-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:39 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>16&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3334199\" data-ts=\"1519662719\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CPRT\" target=\"_blank\">CPRT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3334199-copart-runs-to-new-high-after-earnings\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Copart runs to new high after earnings</a></h4><ul> <li>Copart (<a href='https://seekingalpha.com/symbol/CPRT' title='Copart, Inc.'>CPRT</a> <font color='green'>+3%</font>) trades higher after topping estimates with its FQ2 report.</li> <li>Net income rose 56% Y/Y to $103.3M during the quarter.</li> <li>Shares of the online auction firm reached a 52-week high of $49.99 earlier in the day before retreating back a bit.</li> <li>Previously: <a href=\"https://seekingalpha.com/news/3334135-copart-beats-0_07-beats-revenue\" target=\"_blank\">Copart beats by $0.07, beats on revenue</a> (Feb. 26)</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3334199\" data-linked=\"Copart runs to new high after earnings\" data-tweet=\"$CPRT - Copart runs to new high after earnings https://seekingalpha.com/news/3334199-copart-runs-to-new-high-after-earnings?source=tweet\" data-url=\"https://seekingalpha.com/news/3334199-copart-runs-to-new-high-after-earnings\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:31 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3334197\" data-ts=\"1519662540\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GS\" target=\"_blank\">GS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3334197-big-deal-in-cryptos-circle-buys-poloniex\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Big deal in cryptos: Circle buys Poloniex</a></h4><ul><li>The deal may create a Wall Street-style crypto-related financial services giant, <a href=\"http://fortune.com/2018/02/26/circle-cryptocurrency-trade-bitcoin/\" target=\"_blank\">writes Fortune's Robert Hackett</a>.</li><li>Backed by Goldman Sachs (NYSE:<a href='https://seekingalpha.com/symbol/GS' title='Goldman Sachs Group Inc.'>GS</a>), Circle (through its Circle Trade platform) is the gorilla in institutional cryptocurrency trading. The Circle Trade desk handles more than $2B per month in transactions, with minimum deal size of $250K, according to Hackett. Revenue in the quarter ended in January topped $60M.</li><li>Today, it's announced the purchase of Poloniex, one of the globe's most active crypto exchanges, for a reported price of around $400M.</li><li>In addition to making Circle an instant threat to Coinbase (<a href='https://seekingalpha.com/symbol/COINB' title='Coinbase'>COINB</a>), writes Hackett, the acquisition sets the stage for a step up in the \"mainstreaming\" of cryptocurrencies.</li><li>Cryptos are in rally mode today, with Bitcoin&nbsp;<font color='green'>higher by 7.5%</font>&nbsp;to $10,350.</li><li>Related tickers: <a href='https://seekingalpha.com/symbol/GBTC' title='Grayscale Bitcoin Trust &#40;BTC&#41;'>OTCQX:GBTC</a>, <a href='https://seekingalpha.com/symbol/COIN' title='Winklevoss Bitcoin Trust ETF'>COIN</a>, <a href='https://seekingalpha.com/symbol/RIOT' title='Riot Blockchain, Inc.'>RIOT</a>, <a href='https://seekingalpha.com/symbol/OSTK' title='Overstock.com, Inc.'>OSTK</a>, <a href='https://seekingalpha.com/symbol/SSC-OLD' title='Seven Stars Cloud Group, Inc.'>SSC-OLD</a>, <a href='https://seekingalpha.com/symbol/MARA' title='Marathon Patent Group, Inc.'>MARA</a>, <a href='https://seekingalpha.com/symbol/UEPS' title='Net 1 UEPS Technologies, Inc.'>UEPS</a>, <a href='https://seekingalpha.com/symbol/BITCF' title='First Bitcoin Capital Corp.'>OTC:BITCF</a>, <a href='https://seekingalpha.com/symbol/XNET' title='Xunlei Limited'>XNET</a>, <a href='https://seekingalpha.com/symbol/GROW' title='U.S. Global Investors, Inc.'>GROW</a>, <a href='https://seekingalpha.com/symbol/BTSC' title='Bitcoin Services, Inc.'>OTCPK:BTSC</a>, <a href='https://seekingalpha.com/symbol/BTCS' title='BTCS Inc.'>OTCQB:BTCS</a>, <a href='https://seekingalpha.com/symbol/MGTI' title='MGT Capital Investments, Inc.'>OTCQB:MGTI</a>, <a href='https://seekingalpha.com/symbol/BTLLF' title='Interbit Ltd.'>OTCPK:BTLLF</a> <a href='https://seekingalpha.com/symbol/SRAX' title='Social Reality Inc.'>SRAX</a>, <a href='https://seekingalpha.com/symbol/GAHC' title='Global Arena Holding, Inc.'>OTCPK:GAHC</a>, <a href='https://seekingalpha.com/symbol/ARSC' title='American Security Resources Corp.'>OTC:ARSC</a>, <a href='https://seekingalpha.com/symbol/USTC' title='USA Real Estate Holding Co'>OTCPK:USTC</a>, <a href='https://seekingalpha.com/symbol/BLKCF' title='Global Blockchain Technologies Corp.'>OTCPK:BLKCF</a>, <a href='https://seekingalpha.com/symbol/COINB' title='Coinbase'>COINB</a>, <a href='https://seekingalpha.com/symbol/LFIN' title='LongFin Corp.A'>OTCPK:LFIN</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3334197\" data-linked=\"Big deal in cryptos: Circle buys Poloniex\" data-tweet=\"$GS $GS $COINB - Big deal in cryptos: Circle buys Poloniex https://seekingalpha.com/news/3334197-big-deal-in-cryptos-circle-buys-poloniex?source=tweet\" data-url=\"https://seekingalpha.com/news/3334197-big-deal-in-cryptos-circle-buys-poloniex\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:29 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>47&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3334195\" data-ts=\"1519662337\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ATNM\" target=\"_blank\">ATNM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3334195-actinium-pharma-down-18-after-discounting-rights-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Actinium Pharma down 18% after discounting rights offering</a></h4><ul><li>Nano cap Actinium Pharmaceuticals (<a href='https://seekingalpha.com/symbol/ATNM' title='Actinium Pharmaceuticals, Inc.'>ATNM</a> <font color='red'>-18.4%</font>) slumps on almost double normal volume after <a href=\"https://seekingalpha.com/pr/17084375-actinium-pharmaceuticals-reiterates-previously-announced-expiration-date-march-2-2018-5-00-pm\" target=\"_blank\">discounting </a>its subscription rights offering to $0.50 per unit (50M units).</li><li>Each unit consists of one share of common stock, 1/4 of a 12-month Series A warrant to purchase one share of common at $0.60 and 3/4 of a 30-month Series B warrant to purchase one share of common at $0.70.</li><li>The rights offering to stockholders and certain warrant holders will expire on Friday, March 2 unless extended.</li><li>The <a href=\"https://www.sec.gov/Archives/edgar/data/1388320/000121390018001918/f8k021518_actiniumpharma.htm\" target=\"_blank\">original offering </a>was 35,714,285 units at $0.70 per unit. The Series A and Series B warrants were exercisable at $0.90 and $1.10, respectively.</li></ul><div class=\"tiny-share-widget\" data-id=\"3334195\" data-linked=\"Actinium Pharma down 18% after discounting rights offering\" data-tweet=\"$ATNM - Actinium Pharma down 18% after discounting rights offering https://seekingalpha.com/news/3334195-actinium-pharma-down-18-after-discounting-rights-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3334195-actinium-pharma-down-18-after-discounting-rights-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:25 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3334194\" data-ts=\"1519662176\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WBT\" target=\"_blank\">WBT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3334194-welbiltminus-6_7-after-q4-rev-miss-mixed-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Welbilt -6.7% after Q4 rev. miss, mixed guidance</a></h4><ul><li>        Welbilt (NYSE:<a href='https://seekingalpha.com/symbol/WBT' title='Welbilt, Inc.'>WBT</a>) shares&nbsp;<font color='red'>plunge 6.7%</font>&nbsp;after premarket Q4 results that beat EPS estimates but missed on revenue with a 3.4% Y/Y drop.</li><li>               Mixed FY18 guidance: Revenue, $1.55B to $1.59B (consensus: $1.52B); EPS, $0.80 to $0.90 (consensus: $0.94).&nbsp;</li><li>               Segment performance: Americas, $291M (-4.6% Y/Y) with third-party net sales at $260.8M (-2%); EMEA, $72.3M (-3.3%) with third-party net sales of $58.8M (-6.7%); APAC, $51.8M (-8.2%) with third-party net sales of $46.3M (-6.7%).&nbsp;</li><li>                  Tax reform impact: Income tax expense net decrease of $32M in Q4.    </li><li>               <a href=\"https://seekingalpha.com/pr/17083758-welbilt-reports-solid-fourth-quarter-full-year-operating-results\" target=\"_blank\">Press release</a>&nbsp; &nbsp;&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3334026-welbilt-announces-agreement-acquire-crem-international-224m\" target=\"_blank\">Welbilt announces agreement to acquire Crem International for $224M</a> (Feb. 26)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3334025-welbilt-beats-0_02-misses-revenue\" target=\"_blank\">Welbilt beats by $0.02, misses on revenue</a> (Feb. 26)</li></ul><div class=\"tiny-share-widget\" data-id=\"3334194\" data-linked=\"Welbilt -6.7% after Q4 rev. miss, mixed guidance\" data-tweet=\"$WBT - Welbilt -6.7% after Q4 rev. miss, mixed guidance https://seekingalpha.com/news/3334194-welbiltminus-6_7-after-q4-rev-miss-mixed-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3334194-welbiltminus-6_7-after-q4-rev-miss-mixed-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:22 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3334193\" data-ts=\"1519661432\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SDRL\" target=\"_blank\">SDRL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3334193-seadrill-says-bondholders-join-restructuring-in-settlement\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Seadrill says more bondholders join restructuring in settlement</a></h4><ul>     <li>Seadrill (<a href='https://seekingalpha.com/symbol/SDRL' title='Seadrill Limited &#40;New&#41;'>SDRL</a> <font color='green'>+3.7%</font>) says ~70% of its bondholders by principal amount have signed an agreement to <a href=\"https://globenewswire.com/news-release/2018/02/26/1387200/0/en/SDRL-Seadrill-Announces-Global-Settlement-in-Chapter-11-Cases.html\" target=\"_blank\">support the company&rsquo;s restructuring</a>, as 99% of its bank lenders by principal amount previously signed and remain party to the agreement.</li>     <li>SDRL says the settlement adds additional bondholders  as commitment parties to its ~$1B new capital raise and includes agreements over the amount and treatment of claims by the Samsung Heavy Industries and Daewoo shipyards that are party to newbuild contracts with the company.</li>     <li>\"We now have virtually all of our bank lenders, a supermajority of our bonds, the official creditors'  committee, newbuild contract counterparties, and our largest shareholder supporting our restructuring,\"&nbsp;SDRL says. \"We look forward to the successful implementation of the transaction in the near future.\"</li></ul><div class=\"tiny-share-widget\" data-id=\"3334193\" data-linked=\"Seadrill says more bondholders join restructuring in settlement\" data-tweet=\"$SDRL - Seadrill says more bondholders join restructuring in settlement https://seekingalpha.com/news/3334193-seadrill-says-bondholders-join-restructuring-in-settlement?source=tweet\" data-url=\"https://seekingalpha.com/news/3334193-seadrill-says-bondholders-join-restructuring-in-settlement\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:10 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>43&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3334192\" data-ts=\"1519661331\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DIN\" target=\"_blank\">DIN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3334192-raymond-james-rally-extending-dine-brands-global\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Raymond James rally extending at Dine Brands Global</a></h4><ul> <li>Raymond James upgrades Dine Brands Global (<a href='https://seekingalpha.com/symbol/DIN' title='Dine Brands Global, Inc.'>DIN</a> <font color='green'>+4.4%</font>) to Outperform from Market Perform after accounting for improvement in the Applebee's business.</li> <li>The upgrades arrives even after shares of Dine Brands roared over 20% in the last week. The price target from RJ of <a href=\"https://247wallst.com/investing/2018/02/26/top-analyst-upgrades-and-downgrades-baker-hughes-bp-duke-energy-finish-line-hp-schlumberger-ups-workday-and-more/\" target=\"_blank\">$85</a>&nbsp; on the restaurant stock reps a swing higher of another 18%.</li>   </ul><div class=\"tiny-share-widget\" data-id=\"3334192\" data-linked=\"Raymond James rally extending at Dine Brands Global\" data-tweet=\"$DIN - Raymond James rally extending at Dine Brands Global https://seekingalpha.com/news/3334192-raymond-james-rally-extending-dine-brands-global?source=tweet\" data-url=\"https://seekingalpha.com/news/3334192-raymond-james-rally-extending-dine-brands-global\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:08 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3334166\" data-ts=\"1519660942\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/XTNT\" target=\"_blank\">XTNT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3334166-healthcare-top-5-gainers-losers-of-11-00-2-26-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Healthcare - Top 5 Gainers / Losers as of 11:00 am (2/26/2018)</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/XTNT' title='Xtant Medical Holdings, Inc.'>XTNT</a> <font color='green'>+14%</font>. <a href='https://seekingalpha.com/symbol/APLS' title='Apellis Pharmaceuticals, Inc.'>APLS</a> <font color='green'>+12%</font>. <a href='https://seekingalpha.com/symbol/ACHN' title='Achillion Pharmaceuticals, Inc.'>ACHN</a> <font color='green'>+11%</font>. <a href='https://seekingalpha.com/symbol/TNDM' title='Tandem Diabetes Care, Inc.'>TNDM</a> <font color='green'>+10%</font>. <a href='https://seekingalpha.com/symbol/MESO' title='Mesoblast'>MESO</a> <font color='green'>+10%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/ABIO' title='ARCA biopharma, Inc.'>ABIO</a> <font color='red'>-61%</font>. <a href='https://seekingalpha.com/symbol/IRIX' title='IRIDEX Corporation'>IRIX</a> <font color='red'>-24%</font>. <a href='https://seekingalpha.com/symbol/MDXG' title='MiMedx Group Inc.'>OTC:MDXG</a> <font color='red'>-21%</font>. <a href='https://seekingalpha.com/symbol/IFRX' title='InflaRx N.V.'>IFRX</a> <font color='red'>-15%</font>. <a href='https://seekingalpha.com/symbol/AKTX' title='Akari Therapeutics Plc'>AKTX</a> <font color='red'>-11%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3334166\" data-linked=\"Healthcare - Top 5 Gainers / Losers as of 11:00 am (2/26/2018)\" data-tweet=\"$XTNT $XTNT $APLS - Healthcare - Top 5 Gainers / Losers as of 11:00 am (2/26/2018) https://seekingalpha.com/news/3334166-healthcare-top-5-gainers-losers-of-11-00-2-26-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3334166-healthcare-top-5-gainers-losers-of-11-00-2-26-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:02 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3334191\" data-ts=\"1519660920\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ECYT\" target=\"_blank\">ECYT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3334191-endocyte-readies-late-stage-study-of-lu-psmaminus-617-in-prostate-cancer-shares-up-7\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Endocyte readies late-stage study of Lu-PSMA-617 in prostate cancer; shares up 7%</a></h4><ul><li>Endocyte (<a href='https://seekingalpha.com/symbol/ECYT' title='Endocyte, Inc.'>ECYT</a> <font color='green'>+6.9%</font>) launches a Phase 3 clinical trial, VISION, assessing Lu-PSMA-617 in patients with progressive prostate-specific membrane antigen &#40;PSMA&#41;-positive metastatic castration-resistant prostate cancer (mCRPC) who have received at least one novel androgen axis drug &#40;NAAD&#41; and at least one taxane regimen. Enrollment will commence next quarter.</li><li>The primary endpoint of the open-label, 750-subject study is overall survival &#40;OS&#41; in patients receiving Lu-PSMA-617 plus best supportive care alone or in combination with a NAAD compared to best supportive care alone or in combination a NAAD. Patients in the treatment group will receive Lu-PSMA-617 intravenously every six weeks up to six cycles.</li><li>Interim data from 50 patients in an Australia-based study will be presented at ASCO in June.</li><li>Lu-PSMA-617, licensed from ABX GmbH, selectively delivers short-range beta-emitting radioactive isotope lutetium to tumor cells that express prostate-specific membrane antigen &#40;PSMA&#41;.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3299495-stats-feuerstein-rains-endocytes-parade-says-prostate-drug-likely-work-shares-8-percent\" target=\"_blank\">STAT's Feuerstein rains on Endocyte's parade, says prostate drug not likely to work; shares down 8% premarket</a> (Oct. 5, 2017)</li></ul><div class=\"tiny-share-widget\" data-id=\"3334191\" data-linked=\"Endocyte readies late-stage study of Lu-PSMA-617 in prostate cancer; shares up 7%\" data-tweet=\"$ECYT - Endocyte readies late-stage study of Lu-PSMA-617 in prostate cancer; shares up 7% https://seekingalpha.com/news/3334191-endocyte-readies-late-stage-study-of-lu-psmaminus-617-in-prostate-cancer-shares-up-7?source=tweet\" data-url=\"https://seekingalpha.com/news/3334191-endocyte-readies-late-stage-study-of-lu-psmaminus-617-in-prostate-cancer-shares-up-7\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:02 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3334187\" data-ts=\"1519660141\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AAPL\" target=\"_blank\">AAPL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3334187-apple-confirms-using-google-cloud-cook-will-co-chair-china-business-forum\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Apple confirms using Google Cloud; Cook will co-chair China business forum</a></h4><ul><li>        Apple (NASDAQ:<a href='https://seekingalpha.com/symbol/AAPL' title='Apple Inc.'>AAPL</a>) <a href=\"https://www.cnbc.com/2018/02/26/apple-confirms-it-uses-google-cloud-for-icloud.html\" target=\"_blank\">uses</a> Google (<a href='https://seekingalpha.com/symbol/GOOG' title='Alphabet, Inc. Cl C'>GOOG</a>, <a href='https://seekingalpha.com/symbol/GOOGL' title='Alphabet, Inc. Cl A'>GOOGL</a>) Cloud for storing iCloud user data.</li><li>                  Media outlets had reported on Google&rsquo;s iCloud business win in 2016, but neither company ever confirmed the news.    </li><li>               The confirmation finally came in last month&rsquo;s iOS Security Guide update and was spotted by CNBC&rsquo;s Jordan Novet.&nbsp; &nbsp;&nbsp;</li><li>               Google Cloud and its G Suite line of cloud productivity apps contribute $1B in revenue per quarter to parent company Alphabet.&nbsp;</li><li>               China forum: CEO Tim Cook will <a href=\"https://www.wsj.com/articles/apples-china-lesson-think-different-but-not-too-different-1519642914?mod=pls_whats_news_us_business_f\" target=\"_blank\">co-chair the China Development Forum</a> next month. The Forum showcases global businesses and marks Cook&rsquo;s fifth notable appearance in the region in roughly a year.&nbsp;</li><li>               Apple&rsquo;s recent concessions to the Chinese government have earned criticism. The company blocked virtual private network apps from the App Store in the region and will this week move iCloud customer data to mainland servers.&nbsp;</li><li>                  Apple&rsquo;s market share has dropped from 13% in 2015 to 9% last year, which moved the company from third place to fifth, according to Canalys research.    </li><li>               Apple shares are&nbsp;<font color='green'>up 1.2%</font>&nbsp;in a good day for FANG stocks.&nbsp;</li><li>               Alphabet Class A shares are&nbsp;<font color='green'>up 0.5%</font>.&nbsp;&nbsp;&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3334056-buffett-talks-shop-annual-letter\" target=\"_blank\">Buffett talks shop after annual letter</a> (Feb. 26)</li></ul><div class=\"tiny-share-widget\" data-id=\"3334187\" data-linked=\"Apple confirms using Google Cloud; Cook will co-chair China business forum\" data-tweet=\"$AAPL $AAPL $GOOG - Apple confirms using Google Cloud; Cook will co-chair China business forum https://seekingalpha.com/news/3334187-apple-confirms-using-google-cloud-cook-will-co-chair-china-business-forum?source=tweet\" data-url=\"https://seekingalpha.com/news/3334187-apple-confirms-using-google-cloud-cook-will-co-chair-china-business-forum\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:49 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>126&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3334184\" data-ts=\"1519659735\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KOOL\" target=\"_blank\">KOOL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3334184-cesca-launches-next-gen-cord-blood-processing-system-shares-up-3\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cesca launches next-gen cord blood processing system; shares up 3%</a></h4><ul><li>Thinly traded nano cap Cesca Therapeutics (<a href='https://seekingalpha.com/symbol/KOOL' title='Cesca Therapeutics Inc'>KOOL</a> <font color='green'>+2.8%</font>) <a href=\"https://seekingalpha.com/pr/17083885-cesca-therapeutics-inc-announces-commercial-launch-axp-ii-system-advanced-cord-blood\" target=\"_blank\">announces </a>the commercial launch of its AXP II system for the advanced isolation, collection and storage of hematopoietic stem cell concentrates from cord blood and peripheral blood.</li><li>The original AXP was launched in 2006. The AXP II offers several enhancements, a docking station and proprietary software.</li></ul><div class=\"tiny-share-widget\" data-id=\"3334184\" data-linked=\"Cesca launches next-gen cord blood processing system; shares up 3%\" data-tweet=\"$KOOL $THMO - Cesca launches next-gen cord blood processing system; shares up 3% https://seekingalpha.com/news/3334184-cesca-launches-next-gen-cord-blood-processing-system-shares-up-3?source=tweet\" data-url=\"https://seekingalpha.com/news/3334184-cesca-launches-next-gen-cord-blood-processing-system-shares-up-3\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:42 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3334183\" data-ts=\"1519659603\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3334183-soft-new-home-sales-number-buoys-bond-market\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Soft new home sales number buoys bond market</a></h4><ul><li>This just in:&nbsp; Bonds are higher for a third straight session.</li><li>Helping sentiment today <a href=\"https://seekingalpha.com/news/3334177-new-home-sales-short-expectations\" target=\"_blank\">was a stinker of a</a> new home sales number for January, with the seasonally-adjusted annualized rate of 593K down 7.8% from December and well shy of hopes for 648K. It's also 1% weaker than the rate in January a year ago. This report's numbers are subject to sometimes sizable revisions.</li><li>In any case, the 10-year Treasury yield - at one point last week flirting with 3% - is off another 3.6 basis points today to 2.83%.</li><li>In other fixed-income news, bullish contrarians may surely be hearing a bell ringing for a top in yields after <a href=\"https://www.bloomberg.com/news/articles/2018-02-25/goldman-says-stocks-may-plunge-25-if-10-year-yield-hits-4-5\" target=\"_blank\">Goldman over the weekend</a> started talking about the implications of the 10-year yield hitting 4.5%. How about punching through 3% first?</li><li>Put Morgan Stanley in that group of contrarians. <a href=\"https://seekingalpha.com/news/3334016-morgan-stanley-gets-bullish-bonds\" target=\"_blank\">The rates strategy team there</a> is happy to take the other side of bearish bets by the likes of Goldman and Warren Buffett.</li><li><a href='https://seekingalpha.com/symbol/TLT' title='iShares 20+ Year Treasury Bond ETF'>TLT</a>&nbsp;<font color='green'>+0.6%</font>, <a href='https://seekingalpha.com/symbol/TBT' title='ProShares UltraShort 20+ Year Treasury ETF'>TBT</a>&nbsp;<font color='red'>-1.2%</font></li></ul><div class=\"tiny-share-widget\" data-id=\"3334183\" data-linked=\"Soft new home sales number buoys bond market\" data-tweet=\"$TLT $TBT - Soft new home sales number buoys bond market https://seekingalpha.com/news/3334183-soft-new-home-sales-number-buoys-bond-market?source=tweet\" data-url=\"https://seekingalpha.com/news/3334183-soft-new-home-sales-number-buoys-bond-market\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:40 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3334180\" data-ts=\"1519659310\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MDXG\" target=\"_blank\">MDXG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3334180-mimedx-still-under-pressure-down-19\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">MiMedx still under pressure, down 19%</a></h4><ul><li>Embattled MiMedx (<a href='https://seekingalpha.com/symbol/MDXG' title='MiMedx Group Inc.'>OTC:MDXG</a> <font color='red'>-19.2%</font>) is down on almost triple normal volume an hour into the session. Apparently, there are headlines floating about that the Feds are investigating its sales and distribution practices, an inquiry the company says it knows nothing about. It also reiterates its denial of any wrongdoing in the matter.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3333880-mimedx-reiterates-confidence-performance-sees-material-effect-investigation\" target=\"_blank\">MiMedx reiterates confidence in performance, sees no material effect from investigation</a> (Feb. 23)</li><li><strong>Update</strong>: Bloomberg <a href=\"https://www.bloomberg.com/news/articles/2018-02-26/u-s-is-said-to-probe-mimedx-s-federal-contracts-accounting\" target=\"_blank\">reports </a>that \"persons familiar with the matter\" say the U.S. Department of Justice is looking into whether the company has overcharged the government for its tissue-repair products in addition to its distribution practices, including alleged \"channel stuffing.\"</li></ul><div class=\"tiny-share-widget\" data-id=\"3334180\" data-linked=\"MiMedx still under pressure, down 19%\" data-tweet=\"$MDXG - MiMedx still under pressure, down 19% https://seekingalpha.com/news/3334180-mimedx-still-under-pressure-down-19?source=tweet\" data-url=\"https://seekingalpha.com/news/3334180-mimedx-still-under-pressure-down-19\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:35 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3334161\" data-ts=\"1519659132\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GOV-OLD\" target=\"_blank\">GOV-OLD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3334161-government-properties-down-6-after-q4-earnings-miss\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Government Properties down 6% after Q4 earnings miss</a></h4><ul><li>Q4 normalized FFO of $49.1M or $0.50 per share down from $41.5M and $0.58 one year ago. Dividend is $0.43.</li><li>Consolidated property cash NOI is $64.4M vs $39.3M last year.</li><li>Rental income is $316M for full-year 2017 up from $258M one year ago.</li><li>Q4 new and renewal leases are 520,150 sqft at weighted average rent up 3.3% Y/Y. 94.2% of rentable square feet was leased in Q4 vs. 95% last quarter.</li><li><a href=\"http://www.govreit.com/home/default.aspx\" target=\"_blank\">Earnings call</a> at 11 ET</li><li>Previously: <a href=\"https://seekingalpha.com/news/3334115-government-properties-misses-0_04-misses-revenue\" target=\"_blank\">Government Properties misses by $0.04, misses on revenue</a> (Feb. 26)</li><li><a href='https://seekingalpha.com/symbol/GOV-OLD' title='Government Properties Income Trust'>GOV-OLD</a>&nbsp;<font color='red'>-6.2%</font></li></ul><div class=\"tiny-share-widget\" data-id=\"3334161\" data-linked=\"Government Properties down 6% after Q4 earnings miss\" data-tweet=\"$GOV-OLD - Government Properties down 6% after Q4 earnings miss https://seekingalpha.com/news/3334161-government-properties-down-6-after-q4-earnings-miss?source=tweet\" data-url=\"https://seekingalpha.com/news/3334161-government-properties-down-6-after-q4-earnings-miss\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:32 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>22&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3334175\" data-ts=\"1519658157\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RLJE\" target=\"_blank\">RLJE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3334175-amc-networks-buying-rest-of-rlj-entertainment\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">AMC Networks buying rest of RLJ Entertainment</a></h4><ul>   <li>RLJ Entertainment (NASDAQ:<a href='https://seekingalpha.com/symbol/RLJE' title='RLJ Entertainment, Inc.'>RLJE</a>) is <font color='green'>up 10.4%</font> on news it's being <a href=\"https://www.thewrap.com/amc-networks-acquire-remainder-robert-johnsons-rlj-entertainment/\" target=\"_blank\">bought out by AMC Networks</a> (<a href=\"http://seekingalpha.com/symbol/AMCX\" target=\"_blank\">AMCX</a> <font color='red'>-0.7%</font>) in a deal valued at $60M.</li>    <li>The transaction comes at $4.25/share for RLJ; shares closed Friday at $3.87.</li>    <li>AMC will acquire the rest of the company that it doesn't already own, and RLJ founder Robert Johnson will maintain a minority stake.</li>    <li>RLJ does content licensing of independent features as well as direct-to-consumer streaming; it owns Acorn TV and UMC.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3334175\" data-linked=\"AMC Networks buying rest of RLJ Entertainment\" data-tweet=\"$RLJE $RLJE $AMCX - AMC Networks buying rest of RLJ Entertainment https://seekingalpha.com/news/3334175-amc-networks-buying-rest-of-rlj-entertainment?source=tweet\" data-url=\"https://seekingalpha.com/news/3334175-amc-networks-buying-rest-of-rlj-entertainment\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:15 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3334173\" data-ts=\"1519657998\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/X\" target=\"_blank\">X</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3334173-steel-names-open-higher-trump-said-to-lean-toward-harsh-tariffs\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Steel names open higher as Trump said to lean toward harsh tariffs</a></h4><ul>     <li>Steel stocks rally at the open following <a href=\"https://seekingalpha.com/news/3333981-u-s-steel-ak-steel-jump-report-trump-wants-24-percent-steel-tariff\" target=\"_blank\">reports after Friday's close</a> that Pres. Trump wants to impose the harshest tariffs on imports of steel and aluminum: <a href='https://seekingalpha.com/symbol/X' title='United States Steel Corporation'>X</a> <font color='green'>+2.4%</font>, <a href='https://seekingalpha.com/symbol/AKS' title='AK Steel Holding Corp'>AKS</a> <font color='green'>+3.8%</font>, <a href='https://seekingalpha.com/symbol/CLF' title='Cleveland-Cliffs, Inc.'>CLF</a> <font color='green'>+2.9%</font>, <a href='https://seekingalpha.com/symbol/NUE' title='Nucor Corporation'>NUE</a> <font color='green'>+0.6%</font>, <a href='https://seekingalpha.com/symbol/STLD' title='Steel Dynamics, Inc.'>STLD</a> <font color='green'>+0.5%</font>, <a href='https://seekingalpha.com/symbol/RS' title='Reliance Steel & Aluminum Co.'>RS</a> <font color='green'>+0.3%</font>, <a href='https://seekingalpha.com/symbol/SCHN' title='Schnitzer Steel Industries, Inc.'>SCHN</a> <font color='green'>+1.3%</font>.</li>     <li>Trump's apparent wishes would <a href=\"https://www.ft.com/content/55308a2c-1afb-11e8-956a-43db76e69936\" target=\"_blank\">reinforce the recommendations</a> of Commerce Secretary Ross, who has recommended options including imposing a global tariff of at least 24% on imports of steel and 7.7% on aluminum.</li>     <li>ETFs: <a href='https://seekingalpha.com/symbol/SLX' title='VanEck Vectors Steel ETF'>SLX</a>, <a href='https://seekingalpha.com/symbol/JJU-OLD' title='iPath Dow Jones-UBS Aluminum Total Return Sub-IndexS ETN'>JJU-OLD</a>, <a href='https://seekingalpha.com/symbol/FOIL' title='iPath Pure Beta Aluminum ETN'>FOIL</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3334173\" data-linked=\"Steel names open higher as Trump said to lean toward harsh tariffs\" data-tweet=\"$X $X $AKS - Steel names open higher as Trump said to lean toward harsh tariffs https://seekingalpha.com/news/3334173-steel-names-open-higher-trump-said-to-lean-toward-harsh-tariffs?source=tweet\" data-url=\"https://seekingalpha.com/news/3334173-steel-names-open-higher-trump-said-to-lean-toward-harsh-tariffs\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:13 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>19&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3334160\" data-ts=\"1519656377\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMZN\" target=\"_blank\">AMZN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3334160-gbh-insights-ups-amazon-target-to-23-upside-1t-valuation\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">GBH Insights ups Amazon target to 23% upside, $1T valuation</a></h4><ul><li>        GBH Insights <a href=\"https://www.cnbc.com/2018/02/26/amazon-market-cap-could-hit-1-trillion-in-12-months-dan-ives-says.html\" target=\"_blank\">raises</a> its Amazon (NASDAQ:<a href='https://seekingalpha.com/symbol/AMZN' title='Amazon.com, Inc.'>AMZN</a>) price target from $1,500 to $1,850, which is a 23% upside to Friday&rsquo;s close and would represent an over $1T valuation in 12 to 18 months.</li><li>               Analyst Dan Ives says the Prime membership moat is &ldquo;gaining further steam in the field, and the Amazon &lsquo;flywheel effect&rsquo; is further playing out globally among consumers.&rdquo;&nbsp;</li><li>               Ives calls Amazon&rsquo;s consumer retail growth and AWS the &ldquo;1-2 punch&rdquo; backed by the Whole Foods tailwinds and the recent healthcare push.&nbsp;</li><li>               Amazon shares are&nbsp;<font color='green'>up 1.1%</font>.&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3334160\" data-linked=\"GBH Insights ups Amazon target to 23% upside, $1T valuation\" data-tweet=\"$AMZN - GBH Insights ups Amazon target to 23% upside, $1T valuation https://seekingalpha.com/news/3334160-gbh-insights-ups-amazon-target-to-23-upside-1t-valuation?source=tweet\" data-url=\"https://seekingalpha.com/news/3334160-gbh-insights-ups-amazon-target-to-23-upside-1t-valuation\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:46 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>28&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3334159\" data-ts=\"1519656311\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GTT\" target=\"_blank\">GTT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3334159-gtt-to-buy-interoute-for-1_9b-sharesplus-6_8\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">GTT to buy Interoute for \u20ac1.9B; shares +6.8%</a></h4><ul>   <li>GTT Communications (<a href=\"http://seekingalpha.com/symbol/GTT\" target=\"_blank\">GTT</a> <font color='green'>+6.8%</font>) has a <a href=\"https://seekingalpha.com/pr/17083974-gtt-acquire-interoute\" target=\"_blank\">definitive deal to purchase Interoute</a>, operator of one of Europe's biggest independent fiber networks and cloud platforms.</li>    <li>GTT will pay about &euro;1.9B in cash (around $2.3B) in the deal.</li>    <li>Interoute's network covers more than 400 points of presence across 24 metro areas, interconnecting 126 cities across 29 countries. It comprises 15 data centers, 17 virtual data centers and 51 co-location facilities.</li>    <li>The deal also adds more than 1,000 mostly European strategic enterprise and carrier clients to GTT.</li>    <li>Interoute posted revenues of &euro;718M for the 12 months ended Sept. 30.</li>    <li>\"Following our successful, proven acquisition model, we expect to complete this integration within three to four quarters post-close and achieve a post-synergy multiple of seven to eight times Adjusted EBITDA or better on a pro forma basis,\" says GTT CEO Rick Calder.</li>    <li>Conference call about the deal to come Thursday at 10 a.m. ET.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3334159\" data-linked=\"GTT to buy Interoute for \u20ac1.9B; shares +6.8%\" data-tweet=\"$GTT - GTT to buy Interoute for \u20ac1.9B; shares +6.8% https://seekingalpha.com/news/3334159-gtt-to-buy-interoute-for-1_9b-sharesplus-6_8?source=tweet\" data-url=\"https://seekingalpha.com/news/3334159-gtt-to-buy-interoute-for-1_9b-sharesplus-6_8\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:45 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3334154\" data-ts=\"1519655551\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ROSG-OLD\" target=\"_blank\">ROSG-OLD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3334154-rosetta-genomics-genoptix-tie-up-terminated\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Rosetta Genomics - Genoptix tie-up terminated</a></h4><ul><li>Oncology lab services provider Genoptix <a href=\"https://seekingalpha.com/pr/17083950-genoptix-announces-termination-merger-agreement-rosetta-genomics-now-focused-next-steps\" target=\"_blank\">announces </a>that its planned merger with Rosetta Genomics (<a href='https://seekingalpha.com/symbol/ROSG-OLD' title='Rosetta Genomics Ltd.'>ROSG-OLD</a>) has been terminated after the latter failed to secure enough shareholder support for the deal.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3327786-rosetta-genomics-16-percent-failure-get-enough-shareholder-support-genoptix-merger\" target=\"_blank\">Rosetta Genomics down 16% on failure to get enough shareholder support for Genoptix merger</a> (Feb. 2)</li></ul><div class=\"tiny-share-widget\" data-id=\"3334154\" data-linked=\"Rosetta Genomics - Genoptix tie-up terminated\" data-tweet=\"$ROSG-OLD - Rosetta Genomics - Genoptix tie-up terminated https://seekingalpha.com/news/3334154-rosetta-genomics-genoptix-tie-up-terminated?source=tweet\" data-url=\"https://seekingalpha.com/news/3334154-rosetta-genomics-genoptix-tie-up-terminated\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:32 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3334152\" data-ts=\"1519655436\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VEON\" target=\"_blank\">VEON</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3334152-veonplus-3_2-ends-euroset-jv-megafon\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Veon +3.2% as it ends Euroset JV with Megafon</a></h4><ul>   <li>Veon (NASDAQ:<a href='https://seekingalpha.com/symbol/VEON' title='VEON Ltd. ADS'>VEON</a>) is <font color='green'>up 3.2%</font> premarket after announcing that it and Megafon (<a href='https://seekingalpha.com/symbol/MFOYY' title='MegaFon OJSC'>OTC:MFOYY</a>) have completed the transaction to <a href=\"https://seekingalpha.com/pr/17083659-veon-megafon-complete-divestiture-euroset-joint-venture\" target=\"_blank\">end their Euroset joint venture</a>.</li>    <li>VimpelCom (the Russian unit of Veon) acquired half of Euroset's retail stores by paying Megafon 1.25B rubles (about $20M), while Megafon takes over Veon's interest in Euroset.</li><li>The move doubles VimpelCom's retail network in Russia, which it plans to integrate under its Beeline brand under a single-brand strategy.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3334152\" data-linked=\"Veon +3.2% as it ends Euroset JV with Megafon\" data-tweet=\"$VEON $VEON $MFOYY - Veon +3.2% as it ends Euroset JV with Megafon https://seekingalpha.com/news/3334152-veonplus-3_2-ends-euroset-jv-megafon?source=tweet\" data-url=\"https://seekingalpha.com/news/3334152-veonplus-3_2-ends-euroset-jv-megafon\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:30 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3334145\" data-ts=\"1519654773\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FINL\" target=\"_blank\">FINL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3334145-finish-line-jumps-on-susquehanna-confidence\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Finish Line jumps on Susquehanna confidence</a></h4><ul> <li>Finish Line (NASDAQ:<a href='https://seekingalpha.com/symbol/FINL' title='The Finish Line, Inc.'>FINL</a>) pops in early trading after Susquehanna boosts the retailer to a Positive rating from Neutral.</li> <li>The investment firm is confident that the improved comparable sales trends at Finish Line will continue and thinks the company's guidance can be exceeded.</li> <li>On a longer time frame, analyst Sam Poser thinks Sports Direct International (<a href='https://seekingalpha.com/symbol/SDIPF' title='Sports Direct International Plc.'>OTCPK:SDIPF</a>, <a href='https://seekingalpha.com/symbol/SDISY' title='Sports Direct International Plc. ADR'>OTCPK:SDISY</a>) will acquire Finish Line.</li><li>Sources: CNBC, Bloomberg</li><li>FINL&nbsp;<font color='green'>+4.10%</font>&nbsp;premarket to $10.91.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3334145\" data-linked=\"Finish Line jumps on Susquehanna confidence\" data-tweet=\"$FINL $FINL $SDIPF - Finish Line jumps on Susquehanna confidence https://seekingalpha.com/news/3334145-finish-line-jumps-on-susquehanna-confidence?source=tweet\" data-url=\"https://seekingalpha.com/news/3334145-finish-line-jumps-on-susquehanna-confidence\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:19 AM </div></div></li>","count":75,"message":null,"success":true,"today":{"start":1577077200,"end":1577163599,"str":"Monday, December 23, 2019"},"yesterday":{"start":1576990800,"end":1577077199}}